~~The accompanying notes are an integral part of these consolidated financial statements.~~

The accompanying notes are an integral part of these consolidated financial statements.

The accompanying notes are an integral part of these consolidated financial statements

The accompanying notes are an integral part of these consolidated financial statements.

~~The accompanying notes are an integral part of these consolidated financial statements.~~

Reference is made herein to the notes to consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014.

During the second quarter of 2014, the Company recorded a goodwill impairment charge of $380,000 in connection with the sale of our Schreiber, Yonley and Associates, Inc. (“SYA”) subsidiary which was completed on July 29, 2014.

4.	~~Capital Stock,~~ Stock Plans and Stock Based Compensation

The Company has certain stock option plans under which it awards incentive and non-qualified stock options to employees, officers, and outside directors. No

On September 17, 2015, the Company granted an aggregate of 12,000 non-qualified stock options (“NQSOs”) from the Company’s 2003 Outside Directors Stock Plan (“2003 Stock Plan”) to five of the seven re-elected directors at our Annual Meeting of Stockholders held on September 17, 2015. Two of the directors are not eligible to receive options under the 2003 Stock Plan as they are employees of the Company or its subsidiaries. Dr. Centofanti is the Company’s Chief Executive Officer and Mr. John Climaco is an Executive Vice President of Perma-Fix Medical S.A. (effective June 2, 2015), the Company’s majority-owned Polish subsidiary. The NQSOs granted were ~~granted during~~for a contractual term of ten years with a vesting period of six months. The exercise price of the ~~first six months of 2015 or 2014.~~NQSOs was $4.19 per share, which was equal to the Company’s closing stock price the day preceding the grant date, pursuant to the 2003 Stock Plan.

As of ~~June~~September 30, 2015, the Company had an aggregate of 55,000 employee stock options outstanding (from the 2010 Stock Option Plans), of which ~~none~~18,333 are vested. The weighted average exercise price of the ~~55,000~~18,333 outstanding and fully vested employee stock options is $5.00 with a remaining weighted contractual life of ~~5.0~~4.8 years. Additionally, wethe Company had an aggregate of ~~166,635~~163,200 outstanding director stock options (from the 2003 ~~Outside Directors Stock~~ Plans), of which ~~all~~151,200 are vested. The weighted average exercise price of the ~~166,635~~151,200 outstanding and fully vested director stock options is ~~$8.88~~$8.89 with a remaining weighted contractual life of ~~4.6~~4.8 years.

The summary of the Company’s total Stock Option Plans as of ~~June~~September 30, 2015, and 2014, and changes during the periods then ended, are presented below. The Company’s Plans consist of the ~~2010~~2004 and ~~2004~~2010 Stock Option Plans and the 2003 ~~Outside Directors~~ Stock Plans:

Shares

Weighted Average
Exercise Price

Weighted Average Remaining Contractual Term (years)

Aggregate Intrinsic Value

Options outstanding Janury 1, 2015
239,023 $ 7.81
Granted
— —
Exercised
(2,388 ) 2.79 $ 3,248
Forfeited/expired
(15,000 ) 7.10
Options outstanding end of period⁽¹⁾
221,635 7.91 4.7 $ 18,869
Options exercisable at June 30, 2015⁽¹⁾
166,635 $ 8.88 4.6 $ 18,869
Options vested and expected to be vested at June 30, 2015
212,835 $ 8.04 4.7 $ 18,869

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Options outstanding Janury 1, 2015		239,023		$	7.81
Granted		12,000			4.19
Exercised		(3,423	)		2.79			$	4,298
Forfeited		(29,400	)		8.13
Options outstanding End of Period⁽¹⁾		218,200			7.65		5.1	$	25,464
Options Exercisable at September 30, 2015⁽¹⁾		169,533		$	8.47		4.8	$	25,464
Options Vested and expected to be vested at September 30, 2015		212,333		$	7.72		5.1	$	25,464

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Options outstanding Janury 1, 2014		362,800		$	9.53
Granted		71,800			4.70
Exercised		(1,257	)		2.79			$	2,319
Forfeited		(187,000	)		10.04
Options outstanding End of Period⁽¹⁾		246,343			7.77		5.1	$	23,065
Options Exercisable at September 30, 2014⁽¹⁾		174,543		$	9.04		4.4	$	21,049
Options Vested and expected to be vested at September 30, 2014		237,543		$	7.87		5.0	$	23,065

Shares

Weighted Average Exercise Price

Weighted Average Remaining Contractual Term (years)

Aggregate Intrinsic Value

Options outstanding Janury 1, 2014
362,800 $ 9.53
Granted
— —
Exercised
— — —
Forfeited/expired
(62,000 ) 7.96
Options outstanding end of period⁽¹⁾
300,800 9.85 2.8 $ 41,070
Options exercisable at June 30, 2014⁽¹⁾
300,800 $ 9.85 2.8 $ 41,070
Options vested and expected to be vested at June 30, 2014
300,800 $ 9.85 2.8 $ 41,070

⁽¹⁾~~Options with exercise prices ranging from $2.79 to $14.75~~

The Company estimates ~~the~~ fair value of stock options using the Black-Scholes valuation model. Assumptions used to estimate the fair value of stock options granted include the exercise price of the award, the expected term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and the expected annual dividend yield. The fair value of the options granted during the nine months ended September 30, 2015 and 2014 and the related assumptions used in the Black-Scholes option model used to value the options granted were as follows (No options were granted to employees during the nine months ended September 30, 2015):

	Outside Director Stock Options Granted
	September 30, 2015		September 30, 2014
Weighted-average fair value per share		$2.84		$2.73
Risk -free interest rate⁽¹⁾		2.21%		2.63%
Expected volatility of stock⁽²⁾		57.98%		59.59%
Dividend yield		None		None
Expected option life⁽³⁾(years)		10.0		10.0

	Employee Stock Option Granted
	as of September 30, 2014
Weighted-average fair value per share		$2.88
Risk -free interest rate⁽¹⁾		1.91%
Expected volatility of stock⁽²⁾		61.84%
Dividend yield		None
Expected option life⁽³⁾(years)		6.0

⁽¹⁾The risk-free interest rate is based on the U.S. Treasury yield in effect at the grant date over the expected term of the option.

⁽²⁾The expected volatility is based on historical volatility from our traded Common Stock over the expected term of the option.

⁽³⁾The expected option life is based on historical exercises and post-vesting data.

The following table summarizes stock-based compensation recognized, which is included in selling, general and administrative expenses (“SG&A”) in the accompanying Consolidated Statements of Operations, for the three and ~~six~~nine months ended ~~June~~September 30, 2015 and 2014 for our employee and director stock options.

	Three Months Ended				Six Months Ended					Three Months Ended				��	Nine Months Ended
Stock Options	June 30,				June 30,					September 30,					September 30,
	2015		2014		2015		2014			2015		2014			2015		2014
Employee Stock Options	$	13,000	$	—	$	26,000	$	(39,000	)	$	13,000	$	12,000		$	39,000	$	(27,000	)
Director Stock Options		—		1,000		20,000		22,000			2,000		3,000			23,000		25,000
Total	$	13,000	$	1,000	$	46,000	$	(17,000	)	$	15,000	$	15,000		$	62,000	$	(2,000	)

The Company recognized stock-based compensation expense using a straight-line amortization method over the requisite service period, which is the vesting period of the stock option grant. ASC 718, “Compensation – Stock Compensation” requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has generally estimated forfeiture rates based on historical trends of actual forfeitures. When actual forfeitures vary from our estimates, the Company recognizes the difference in compensation expense in the period the actual forfeitures occur or when options vest. The total stock-based compensation expense for the ~~six~~nine months ended ~~June~~September 30, 2014 included a reduction in expense of approximately $54,000 resulting from the forfeiture of options by Mr. Jim Blankenhorn, our Chief Operating Officer (“COO”), who voluntarily resigned from the Company effective March 28, 2014. The COO was granted an option from the Company’s 2010 Stock Option Plan on July 25, 2011, to purchase up to 60,000 shares of the Company’s Common Stock at $7.85 per share. The options had a six year contractual term with one-third yearly vesting over a three year period.

As of ~~June~~September 30, 2015, the Company has approximately ~~$99,000~~$117,000 of total unrecognized compensation cost related to unvested options, of which ~~$27,000~~$30,000 is expected to be recognized in remaining 2015, ~~$53,000~~$68,000 in 2016, with the remaining $19,000 in 2017.

During the ~~six~~nine months ended ~~June~~September 30, 2015, the Company issued a total of ~~33,910~~55,459 shares of our Common Stock under our 2003 Plan to our outside directors as compensation for serving on our Board of Directors. The Company has recorded approximately $216,000 in compensation expenses (included in SG&A) in connection with the issuance of shares of our Common Stock to our outside directors. Also, an outside director exercised ~~2,388~~3,423 options from the 2003 Stock Plan for the purchase of ~~2,388~~3,423 shares of the Company’s Common Stock at $2.79 per share.

5.	Income (Loss)Per Share

Basic Income (loss) per share is calculated based on the weighted-average number of outstanding common shares during the applicable period. Diluted income (loss) per share is based on the weighted-average number of outstanding common shares plus the weighted-average number of potential outstanding common shares. In periods where they are anti-dilutive, such amounts are excluded from the calculations of dilutive earnings per share. The following table reconciles the income (loss) and average share amounts used to compute both basic and diluted income (loss) per share:

	Three Months Ended						Six Months Ended						Three Months Ended						Nine Months Ended
	June 30,						June 30,						September 30,						September 30,
	(Unaudited)						(Unaudited)						(Unaudited)						(Unaudited)
(Amounts in Thousands, Except for Per Share Amounts)	2015			2014			2015			2014			2015			2014			2015			2014
Net (loss) income attributable to Perma-Fix Environmental Services,Inc., common stockholders:
Net income (loss) attributable to Perma-Fix Environmental Services,Inc., common stockholders:
Income (loss) from continuing operations attributable toPerma-Fix Environmental Services, Inc. common stockholders	$	559		$	(2,361	)	$	(1,282	)	$	(6,063	)	$	1,447		$	2,344		$	165		$	(3,720	)
(Loss) income from discontinuing operations attributable toPerma-Fix Environmental Services, Inc. common stockholders		(713	)		2,372			(936	)		2,105			(377	)		(473	)		(1,313	)		1,633
Net (loss) income attributable to Perma-Fix EnvironmentalServices, Inc. common stockholders	$	(154	)	$	11		$	(2,218	)	$	(3,958	)
Net income (loss) attributable to Perma-Fix EnvironmentalServices, Inc. common stockholders													$	1,070		$	1,871		$	(1,148	)	$	(2,087	)

Basic (loss) income per share attributable to Perma-FixEnvironmental Services, Inc. common stockholders	$	(.01	)	$	—		$	(.19	)	$	(.35	)
Basic income (loss) per share attributable to Perma-FixEnvironmental Services, Inc. common stockholders													$	.09		$	.16		$	(.10	)	$	(.18	)

Diluted (loss) income per share attributable to Perma-FixEnvironmental Services, Inc. common stockholders	$	(.01	)	$	—		$	(.19	)	$	(.35	)
Diluted income (loss) per share attributable to Perma-FixEnvironmental Services, Inc. common stockholders													$	.09		$	.16		$	(.10	)	$	(.18	)

Weighted average shares outstanding:
Basic weighted average shares outstanding		11,505			11,433			11,496			11,426			11,526			11,449			11,506			11,434
Add: dilutive effect of stock options		4			—			—			—			5			8			6			—
Add: dilutive effect of warrants		27			—			—			—			30			33			30			—
Diluted weighted average shares outstanding		11,536			11,433			11,496			11,426			11,561			11,490			11,542			11,434


Potential shares excluded from above weighted average sharecalcualtions due to their anti-dilutive effect include:
Upon exercise of options		202,600			276,800			185,800			276,800
Stock options														183			207			183			207

6.	Long Term Debt

Long-term debt consists of the following at ~~June~~September 30, 2015 and December 31, 2014:

(Amounts in Thousands)	June 30, 2015		December 31, 2014		September 30, 2015		December 31, 2014
Revolving Credit facility dated October 31, 2011, borrowings based upon eligible accountsreceivables, subject to monthly borrowing base calculation, variable interest paidmonthly at option of prime rate (3.25% at June 30, 2015) plus 2.0% or London InterbankOffer Rate ("LIBOR") plus 3.0%, balance due October 31, 2016. Effective interest ratefor the first six months of 2015 was 3.3%.⁽¹⁾	$	1,685	$	—
Term Loan dated October 31, 2011, payable in equal monthly installments of principal of$190, balance due on October 31, 2016, variable interest paid monthly at option of primerate plus 2.5% or LIBOR plus 3.5%. Effective interest rate for the first six months of 2015was 3.7%.⁽¹⁾		7,810		8,952
Revolving Credit facility dated October 31, 2011, borrowings based upon eligible accountsreceivables, subject to monthly borrowing base calculation, variable interest paidmonthly at option of prime rate (3.25% at September 30, 2015) plus 2.0% or London InterbankOffer Rate ("LIBOR") plus 3.0%, balance due October 31, 2016. Effective interest ratefor the first nine months of 2015 was 3.8%.⁽¹⁾					$	307	$	—
Term Loan dated October 31, 2011, payable in equal monthly installments of principal of$190, balance due on October 31, 2016, variable interest paid monthly at option of primerate plus 2.5% or LIBOR plus 3.5%. Effective interest rate for the first nine months of 2015was 3.7%.⁽¹⁾						7,238		8,952
Promissory Notedated February 12, 2013, payable in monthly installments of $10, whichincludes interest and principal, starting February 28, 2013, interest accrues at annual rateof 6.0%, paid in full on January 30, 2015.⁽²⁾		—		10		—		10
Promissory Notedated August 2, 2013, payable in twelve monthly installments of interestonly, starting September 1, 2013 and twenty-four monthly installments of $125 inprincipal plus accrued interest. Interest accrues at annual rate of 2.99%.^{(2) (3)}		1,656		2,363		1,303		2,363
Capital lease (interest at rate of 6.0%)		35		47		29		47
		11,186		11,372		8,877		11,372
Less current portion of long-term debt		3,724		3,733		3,613		3,733
	$	7,462	$	7,639	$	5,264	$	7,639

⁽¹⁾Our Revolving Credit facility is collateralized by our accounts receivable and our Term Loan is collateralized by our property, plant, and equipment.

⁽²⁾Uncollateralized note.

⁽³⁾Net of debt discount of ($~~94,000)~~72,000) and ($137,000) ~~for June~~at September 30, 2015 and December 31, 2014, respectively. See “Promissory Notes and Installment Agreements” below for additional information.

Revolving Credit and Term LoanAgreement

The Company entered into an Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated October 31, 2011, (“Loan Agreement”), with PNC Bank, National Association (“PNC”), acting as agent and lender. The Loan Agreement, as amended (“Amended Loan Agreement”), provides us with the following Credit Facility: (a) up to $12,000,000 revolving credit facility (“Revolving Credit”), subject to the amount of borrowings based on a percentage of eligible receivables (as defined) and (b) a term loan (“Term Loan”) of $16,000,000, which requires monthly installments of approximately $190,000 (based on a seven-year amortization).

The Amended Loan Agreement ~~terminates as of~~matures on October 31, 2016, unless sooner terminated. We may terminate the Amended Loan Agreement upon 90 days’ prior written notice and upon payment in full of our obligations under the Amended Loan Agreement.

Our Credit Facility with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our Credit Facility allowing our lender to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit. The Company met its quarterly fixed charge coverage ratio and minimum tangible adjusted net worth requirements in each of the ~~first and second~~ quarters as of September 30, 2015.

As of ~~June~~September 30, 2015, the availability under our revolving credit agreement was ~~$3,637,000,~~$4,284,000, based on our eligible receivables and ~~includes~~is net of an indefinite reduction of borrowing availability of $1,500,000. On July 28, 2014, the Company entered into an amendment to the Amended Loan Agreement which among other things, authorized the Company to use the $3,850,000 insurance settlement proceeds received on June 30, 2014 by our Perma-Fix of South Georgia, Inc. (“PFSG”) subsidiary (which suffered a fire on August 14, 2013 and is included within our discontinued operations) for working capital purposes but placed an indefinite reduction on our borrowing availability by the $1,500,000 as discussed above.

Promissory Notes and Installment Agreements

On February 12, 2013, the Company entered into an unsecured promissory note (“the new note”) with Timios National Corporation (“TNC”) in the principal amount of approximately $230,000 as a result of a settlement with TNC in connection with certain claims that the Company asserted against TNC for breach of certain representations and covenant subsequent to our acquisition of Safety & Ecology Corporation (“SEC”) from TNC on October 31, 2011. The new note was entered into as a result of the settlement in which a previously issued promissory note that the Company entered into with TNC as partial consideration of the purchase price of SEC was cancelled and terminated and replaced with the new note. Final payment of approximately $10,000 on this note was made in January 2015.

On August 2, 2013, the Company completed a lending transaction with Messrs. Robert Ferguson (who serves as an advisor to the Company’s Board of Directors and is also a member of the Board of Directors for our majority-owned Polish subsidiary, Perma-Fix Medical S.A.) and William Lampson (“collectively, the “Lenders”), whereby the Company borrowed from the Lenders the sum of $3,000,000 pursuant to the terms of a Loan and Security Purchase Agreement and promissory note (the “Loan”) (See payment terms of this promissory note in the table above). In connection with this Loan, the Lenders entered into a Subordination Agreement dated August 2, 2013, with the Company’s Credit Facility lender, whereby the Lenders agreed to subordinate payment under the Loan, and agreed that the Loan will be junior in right of payment to the Credit Facility in the event of default or bankruptcy or other insolvency proceeding by the Company. As consideration for the Company receiving the Loan, the Company issued a Warrant to each Lender to purchase up to 35,000 shares of the Company’s Common Stock at an exercise price based on the closing price of the Company’s Common Stock at the closing of the transaction which was determined to be $2.23. The Warrants are exercisable six months from August 2, 2013 and expire on August 2, 2016. The fair value of the Warrants was estimated to be approximately $59,000 using the Black-Scholes option pricing model. As further consideration for the Loan, the Company also issued an aggregate 90,000 shares of the Company’s Common Stock, with each Lender receiving 45,000 shares. The Company determined the fair value of the 90,000 shares of Common Stock to be approximately $200,000 which was based on the closing price of the stock of $2.23 per share on August 2, 2013. The fair value of the Warrants and Common Stock and the related closing fees incurred from the transaction were recorded as a debt discount, which is being amortized using the effective interest method over the term of the loan as interest expense – financing ~~fees.~~fees in the accompanying Consolidated Statements of Operations.

In the event of default of the promissory note by the Company, the Lenders have the option to receive a cash payment equal to the amount of the unpaid principal balance plus all accrued and unpaid interest (“Payoff Amount”), or the number of whole shares of the Company’s Common Stock equal to the Payoff Amount divided by the closing bid price of the Company’s Common Stock on the date immediately prior to the date of default of the promissory note, as reported by the primary national securities exchange on which the Company’s Common Stock is traded. The maximum number of payoff shares is restricted to less than 20% of the outstanding equity.

7.	Perma-Fix Medical S.A. (“PF Medical”)

On April 4, 2014, the Company completed the acquisition of a controlling interest in a Polish Company, a publicly traded shell company on the NewConnect (alternative share market run by the Warsaw Stock Exchange) in Poland and sold to the Polish shell all of the shares of Perma-Fix Medical Corporation, a Delaware corporation ~~(“PF Medical Corporation”)~~ organized by the Company (incorporated in January 2014). PFPerma-Fix Medical Corporation’s only asset was and is a worldwide license granted by the Company to use, develop and market the new process and technology developed by the Company in the production of Technetium-99 (“Tc-99m”) for medical diagnostic applications. Since the acquired shell company (now named as Perma-Fix Medical S.A. or ~~PF Medical S.A.~~“PF Medical”) did not meet the definition of a business under ASC 805, “Business Combinations”, the transaction was accounted for as a capital transaction. The primary purpose of PF Medical ~~S.A. (which the Company owns 64% of as of June 30, 2015)~~ is to provide a financing vehicle for the research and development (“R&D”) and marketing of its medical isotope or Tc-99m technology used in medical diagnostic testing for potential use throughout the world.

During August 2014, PF Medical ~~S.A.~~ executed stock subscription agreements totaling approximately $2,357,000 for 250,000 shares of its Series E Common Stock to non-U.S. persons in an offshore private placement under Regulation S promulgated under the Securities Act of 1933, as amended (“Securities Act”). In connection with this transaction, ~~as of June 30, 2015,~~ PF Medical ~~S.A.~~ has received approximately $1,545,000 in proceeds, ~~(of~~of which approximately $67,000 was received in the first ~~quarter~~nine months of ~~2015)~~2015, for the 250,000 shares (before deduction for commissions and legal expenses relating to this offering of approximately $242,000). The $67,000 is being held in an escrow account as the proceeds will be used to pay for potential future expenses related to the medical isotope project. The Company has recorded the amount held in escrow as restricted cash on the accompanying Consolidated Balance ~~Sheet.~~Sheets. PF Medical ~~S.A.~~ expects to receive the remaining proceeds for the stock subscription receivables in the amount of approximately ~~$761,000~~$751,000 by December 2015. The remaining stock subscription receivables are offset against non-controlling interest. If PF Medical ~~S.A.~~ does not receive approximately ~~$599,000~~$591,000 of the remaining stock subscription receivables, which represents approximately 68,181 shares, PF Medical ~~S.A.~~ has the option to have the purchaser of such shares transfer all of its rights, title and interest in such shares to PF Medical ~~S.A.~~ or for PF Medical ~~S.A.~~ to be paid for the 68,161 shares with shares of another publicly traded company. ~~See Note 13 – “Subsequent Events” for further information regarding~~

On July 24, 2015, PF Medical ~~S.A.~~and Digirad Corporation, a Delaware corporation (“Digirad”), Nasdaq: DRAD, entered into a multi-year Tc-99m Supplier Agreement (the “Supplier Agreement”) and a Series F Stock Subscription Agreement (the “Subscription Agreement”), (together, the “Digirad Agreements”). The Supplier Agreement became effective upon the completion of the Subscription Agreement. Pursuant to the terms of the Digirad Agreements,Digirad purchased, in a private placement and pursuant to Regulation S under the Securities Act, 71,429 shares of PF Medical’s restricted Series F Stock for an aggregate purchase price of $1,000,000. The issuance of the shares has been approved by the Polish authority. As of September 30, 2015, legal expenses incurred for this offering totaled approximately $29,000. The net proceeds of $971,000 in stock subscription were recorded as non-controlling interest in the accompanying Consolidated Balance Sheets. The 71,429 share investment made by Digirad constituted approximately 5.4% of the outstanding common shares of PF Medical. As a result of this transaction, the Company’s ownership interest in PF Medical diluted from approximately 64.0% to approximately 60.5%. The Supplier Agreement provides, among other things, that upon PF Medical’s commercialization of certain Tc99m generators, Digirad will purchase agreed upon quantities of Tc-99m for its nuclear imaging operations either directly or in conjunction with its preferred nuclear pharmacy supplier and PF Medical will supply Digirad, or its preferred nuclear pharmacy supplier, with Tc-99m at a preferred pricing, subject to certain conditions.

8.	Commitments and Contingencies

Hazardous Waste

In connection with our waste management services, we ~~handle~~treat both hazardous and non-hazardous waste, which we transport to our own, or other, facilities for destruction or disposal. As a result of disposing of hazardous substances, in the event any cleanup is required, we could be considered a potentially responsible party for the costs of the cleanup notwithstanding any absence of fault on our part.

Legal Matters

In the normal course of conducting our business, we are involved in various litigation. We are not a party to any litigation or governmental proceeding which our management believes could result in any judgments or fines against us that would have a material adverse effect on our financial position, liquidity or results of future operations.

Insurance

The Company has a 25-year finite risk insurance policy entered into in June 2003 with American International Group, Inc. (“AIG”), which provides financial assurance to the applicable states for our permitted facilities in the event of unforeseen closure. The policy, as amended, provides for a maximum allowable coverage of $39,000,000 and has available capacity to allow for annual inflation and other performance and surety bond requirements. All of the required payments for this finite risk insurance policy, as amended, were made by 2012. As of ~~June~~September 30, 2015, our financial assurance coverage amount under this policy totaled approximately $38,454,000. The Company has recorded ~~$15,443,000~~$15,452,000 in our sinking fund related to the policy noted above in other long term assets on the accompanying consolidated balance sheets, which includes interest earned of ~~$972,000~~$980,000 on the sinking fund as of ~~June~~September 30, 2015. Interest income for the three and ~~six~~nine month periods ended ~~June~~September 30, 2015, was approximately ~~$6,000~~$9,000 and ~~$14,000,~~$23,000, respectively. Interest income for the three and ~~six~~nine month periods ended ~~June~~September 30, 2014, was approximately $5,000 and ~~$11,000,~~$15,000, respectively. If the Company so elects, AIG is obligated to pay us an amount equal to 100% of the sinking fund account balance in return for complete release of liability from both us and any applicable regulatory agency using this policy as an instrument to comply with financial assurance requirements.

In August 2007, the Company entered into a second finite risk insurance policy for our Perma-Fix Northwest Richland, Inc. (“PFNWR”) facility with AIG. The policy provided an initial $7,800,000 of financial assurance coverage with an annual growth rate of 1.5%, which at the end of the four year term policy, provides maximum coverage of $8,200,000. The Company has made all of the required payments on this policy. As of ~~June~~September 30, 2015, the Company has recorded ~~$5,908,000~~$5,912,000 in our sinking fund related to this policy in other long term assets on the accompanying consolidated balance sheets, which includes interest earned of ~~$208,000~~$212,000 on the sinking fund as of ~~June~~September 30, 2015. Interest income for the three and ~~six~~nine month periods ended ~~June~~September 30, 2015, was approximately ~~$2,000~~$4,000 and ~~$3,000,~~$7,000, respectively. Interest income for the three and ~~six~~nine month periods ended ~~June~~September 30, 2014, was approximately $1,000 and ~~$3,000,~~$4,000, respectively. This policy is renewed annually at the end of the four year term with a nominal fee for the variance between the coverage requirement and the sinking fund balance. The Company has renewed this policy annually from 2011 to ~~2014~~2015 (with fees ranging from $41,000 to $46,000 annually). All other terms of the policy remain substantially unchanged.

Letter of Credits and Bonding Requirements

9.	Discontinued Operations

The Company’s discontinued operations consist of subsidiaries included in our Industrial Segment: (1) subsidiaries divested in 2011 and prior, (2) two previously closed locations, and (3) our PFSG facility. On August 14, 2013, our PFSG facility incurred fire damage which left it non-operational. In 2014, the Company elected not to rebuild the PFSG facility. The Company carried general liability, pollution, property and business interruption, and workers compensation insurance with a maximum deductible of approximately $300,000. On June 20, 2014, the Company entered into a settlement agreement and release with one of its insurance carriers resulting in receipt of approximately $3,850,000 in insurance settlement proceeds on June 30, 2014, which was used ~~to pay down the Company’s Revolving Credit.~~for working capital purposes.

On May 11, 2015, PFSG received a Notice of Violation and proposed Consent Order (“CO”) from the Georgia Department of Natural Resources Environmental Protection Division (“GAEPD”), which alleged certain violations of Georgia ~~Rules for Hazardous Waste Management~~hazardous waste management regulations and ~~the~~ PFSG ~~Hazardous Waste Permit.~~hazardous waste management permit. The proposed CO also established the process for formerly closing the PFSG hazardous waste management facilities, should PFSG elect to do ~~so.~~so; and proposed the assessment of a civil penalty. The final terms of the CO, ~~requests payment of~~including a $201,200 ascivil penalty, ~~for these alleged violations which~~were executed on July 1, 2015. The civil penalty was paid by the Company and recorded in the three months ended June 30, 2015. ~~Pursuant to~~On August 28, 2015, the ~~CO, PFSG shall have 60 days from July 1, 2015 to provide notification of final closure of the entire facility or~~Company notified GAEPD its intent to ~~resume hazardous waste management operations;~~close the PFSG facility; and ~~90 days from July 1,~~on September 29, 2015, ~~to submit~~the Company submitted a ~~post closure plan in~~draft Post-Closure Plan for review and approval by the event PFSG decides to proceed with final closure of the facility.The Company has begun initiating full closure requirements of the facility which will include submittal of a post closure plan to be approved by GAEPD. ~~As a result, PFSG is no longer classified as held for sale.~~

On June 4, 2015, the ~~Company~~Perma-Fix of Michigan, Inc. (“PFMI”) entered into a letter of intent (“LOI”) to sell the property ~~which our Perma-Fix of Michigan, Inc. (“PFMI”)~~PFMI formerly operated on for a sale price of approximately $450,000. PFMI is a closed location. ~~The sale of the property at PFMI is subject to execution of a purchase agreement and completion of due diligence within 90 days of the LOI.~~ As required by ASC 360, the Company concluded that tangible asset impairment existed for PFMI ~~as of June 30, 2015~~ and recorded approximately $150,000 in asset impairment charge ~~which was included in “(Loss) income from discontinued operations, net of taxes”~~ in the ~~accompanying Consolidated Condensed Statements~~second quarter of ~~Operations.~~2015. On September 29, 2015, PFMI entered into a Purchase Agreement (the “Agreement”) for the sale of the property for a sale price of $450,000, which is subject to completion of a due diligence within 45 days of the Agreement. Upon execution of the Agreement, PFMI received $20,000 deposit which is being held in an escrow account (recorded as restricted cash within discontinued operations). Upon closing of the transaction, PFMI is to receive an additional $55,000 in cash in addition to the $20,000 held in escrow and PFMI and the seller will execute a Land Contract (“Contract”) which will provide for, among other things, the remaining balance of the sales price of $375,000 to be paid by the seller in 60 equal monthly installment payments of approximately $7,250, due on or before the 15^th of each month immediately following the execution of the Contract. PFMI retains legal title to the property until the buyer fulfills the obligations under the Contract.

The following table summarizes the results of discontinued operations for the three and ~~six~~nine months ended ~~June~~September 30, 2015 and 2014. Operating loss for the ~~three and six~~nine months ended ~~June~~September 30, 2015 included the civil penalty recorded for PFSG and the asset impairment charge recorded for PFMI during the second quarter of 2015 as discussed above. Operating loss for the ~~three and six~~nine months ended ~~June~~September 30, 2014 included a tangible asset impairment charge of approximately ~~$685,000~~$723,000 (of which $38,000 was recorded during the ~~second~~third quarter of ~~2014~~2014) for PFSG. Remaining operating losses for the periods reflected below were primarily due to costs incurred in the administration and continued monitoring of our discontinued operations, primarily for the PFSG site.

	Three Months Ended						Six Months Ended						Three Months Ended						Nine Months Ended
	June 30,						June 30,						September 30,						September 30,
(Amounts in Thousands)	2015			2014			2015			2014			2015			2014			2015			2014

Net revenues	$	—		$	—		$	—		$	—		$	—		$	—		$	—		$	—
Interest expense	$	—		$	(6	)	$	(1	)	$	(7	)	$	—		$	(1	)	$	(1	)	$	(7	)
Operating loss from discontinued operations	$	(713	)	$	(1,169	)	$	(936	)	$	(1,436	)	$	(356	)	$	(462	)	$	(1,292	)	$	(1,897	)
Income tax expense	$	—		$	—		$	—		$	—		$	21		$	—		$	21		$	—
Gain on insurance settlement of discontinued operations	$	—		$	3,541		$	—		$	3,541
(Loss) gain on insurance settlement of discontinuedoperations													$	—		$	(11	)	$	—		$	3,530
(Loss) income from discontinued operations	$	(713	)	$	2,372		$	(936	)	$	2,105		$	(377	)	$	(473	)	$	(1,313	)	$	1,633

The following table presents the major class of assets of discontinued operations that are classified as held for sale as of ~~June~~September 30, 2015 and December 31, 2014. The held for sale assets may differ at the closing of a sale transaction from the reported balances as of ~~June~~September 30, 2015. Assets and liabilities previously classified as held for sale for PFSG for as of December 31, 2014 have been reclassified to assets and liabilities not held for sale (see charts below) due to the Company’s decision to ~~initiate final closure of PFSG.~~close PFSG as discussed above.

	June 30,		December 31,		September 30,		December 31,
(Amounts in Thousands)	2015		2014		2015		2014

Property	$	450	$	600	$	450	$	600
Total assets held for sale	$	450	$	600	$	450	$	600

The following table presents the major classes of assets and liabilities of discontinued operations that are not held for sale as of ~~June~~September 30, 2015 and December 31, 2014:

	June 30,		December 31,		September 30,		December 31,
(Amounts in Thousands)	2015		2014		2015		2014
Current assets
Other assets	$	22		20	$	37		20
Total current assets		22		20		37		20
Long-term assets
Property, plant and equipment, net⁽¹⁾		81		81		81		81
Total long-term assets		81		81		81		81
Total assets not held for sale	$	103	$	101	$	118	$	101
Current liabilities
Accounts payable	$	915	$	947	$	930	$	947
Accrued expenses and other liabilities		500		462		474		462
Environmental liabilities		627		728		87		728
Total current liabilities		2,042		2,137		1,491		2,137
Long-term liabilities
Closure liabilities		306		302		295		302
Environmental liabilities		369		288		889		288
Total long-term liabilities		675		590		1,184		590
Total liabilities not held for sale	$	2,717	$	2,727	$	2,675	$	2,727

⁽¹⁾

⁽¹⁾~~net of accumulated depreciation of $10,000 for each period presented.~~

^{net of accumulated depreciation of $10,000 for}

^{each period presented.}

10.	Operating Segments

In accordance with ASC 280, “Segment Reporting,” we define an operating segment as a business activity: (a) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the Chief Operating Officer (our Chief Operating Decision Maker) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available.

We currently have two reporting segments, Treatment and Services Segments, which are based on a service offering approach. This, however, excludes corporate headquarters, which do not generate revenue, our discontinued operations (see Note 9 – “Discontinued Operations”), and PF Medical, ~~S.A,~~ a developmental entity whose primary purpose at this time is the R&D and marketing of medical isotope technology used in the medical diagnostic testing and is not generating any revenues (see Note 7 –“Perma-Fix Medical S.A. (“PF Medical”)” for further information of this entity).

Our reporting segments are defined as below:

TREATMENT SEGMENT reporting includes:

nuclear, low-level radioactive, mixed, hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and

R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.

SERVICES SEGMENT, which includes:

On-site waste management services to commercial and government customers;

Technical services, which include:

professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;

integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance;

global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers;

Nuclear services, which include:

technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal;

remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; site construction; logistics; transportation; and emergency response; and

A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) of health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.

The table below presents certain financial information of our operating segments as of and for the three and ~~six~~nine months ended ~~June~~September 30, 2015 and 2014 (in thousands).

Segment Reporting for the Quarter Ended June 30, 2015
Segment Reporting for the Quarter Ended September 30, 2015
	Treatment			Services		Segments Total			Corporate And Other ⁽¹⁾			Consolidated Total			Treatment			Services		Segments Total			Corporate And Others⁽¹⁾			Consolidated Total
Revenue from external customers	$	11,087		$	5,267	$	16,354		$	—		$	16,354		$	10,866		$	6,443	$	17,309		$	—		$	17,309
Intercompany revenues		1			6		7			—			—			32			7		39			—			—
Gross profit		3,335			697		4,032			—			4,032			3,696			1,250		4,946			—			4,946
Interest income		1			—		1			10			11			4			—		4			12			16
Interest expense		(11	)		—		(11	)		(129	)		(140	)		(1	)		—		(1	)		(123	)		(124	)
Interest expense-financing fees		—			—		—			(56	)		(56	)		—			—		—			(56	)		(56	)
Depreciation and amortization		743			190		933			10			943			729			172		901			11			912
Segment profit (loss)		2,258			60		2,318			(1,911	)		407			2,681			507		3,188			(1,904	)		1,284
Expenditures for segment assets		138			—		138			6			144			58			15		73			—			73

Segment Reporting for the Quarter Ended June 30, 2014
Segment Reporting for the Quarter Ended September 30, 2014
	Treatment			Services			Segments Total			Corporate And Other⁽¹⁾			Consolidated Total			Treatment			Services		Segments Total			Corporate And Others⁽¹⁾			Consolidated Total
Revenue from external customers	$	9,396		$	3,261		$	12,657		$	—		$	12,657		$	12,705		$	4,200	$	16,905		$	—		$	16,905
Intercompany revenues		—			33			33			—			—			—			19		19			—			—
Gross profit		1,325			232			1,557			—			1,557			4,943			638		5,581			—			5,581
Interest income		—			—			—			6			6			—			—		—			7			7
Interest expense		(15	)		(1	)		(16	)		(198	)		(214	)		(10	)		—		(10	)		(128	)		(138	)
Interest expense-financing fees		—			2			2			(38	)		(36	)		—			—		—			(52	)		(52	)
Depreciation and amortization		837			248			1,085			13			1,098			748			213		961			12			973
Segment profit (loss)		166			(944	)		(778	)		(1,583	)		(2,361	)		3,985			10		3,995			(1,651	)		2,344
Expenditures for segment assets		120			—			120			—			120			3			39		42			—			42

Segment Reporting for the Six Months Ended June 30, 2015
Segment Reporting for the Nine Months Ended September 30, 2015																Segment Reporting for the Nine Months Ended September 30, 2015
	Treatment			Services			Segments Total			Corporate And Other⁽¹⁾			Consolidated Total				Treatment			Services			Segments Total			Corporate And Others⁽¹⁾			Consolidated Total
Revenue from external customers	$	20,836		$	9,119		$	29,955		$	—		$	29,955			$	31,702		$	15,562		$	47,264		$	—		$	47,264
Intercompany revenues		2			15			17			—			—				34			22			56			—			—
Gross profit		4,570			940			5,510			—			5,510				8,265			2,190			10,455			—			10,455
Interest income		2			—			2			18			20				6			—			6			30			36
Interest expense		(34	)		—			(34	)		(233	)		(267	)			(34	)		—			(34	)		(356	)		(390	)
Interest expense-financing fees		(2	)		—			(2	)		(113	)		(115	)			—			(2	)		(2	)		(169	)		(171	)
Depreciation and amortization		1,507			380			1,887			22			1,909				2,236			552			2,788			33			2,821
Segment profit (loss)		2,443			(241	)		2,202			(3,808	)		(1,606	)			5,124			265			5,389			(5,711	)		(322	)
Expenditures for segment assets		244			13			257			8			265				303			27			330			8			338

Segment Reporting for the Six Months Ended June 30, 2014
Segment Reporting for the Nine Months Ended September 30, 2014																Segment Reporting for the Nine Months Ended September 30, 2014
	Treatment			Services			Segments Total			Corporate And Other⁽¹⁾			Consolidated Total				Treatment			Services			Segments Total			Corporate And Others⁽¹⁾			Consolidated Total
Revenue from external customers	$	17,068		$	6,133		$	23,201		$	—		$	23,201			$	29,773		$	10,333		$	40,106		$	—		$	40,106
Intercompany revenues		—			44			44			—			—				—			64			64			—			—
Gross profit		1,435			215			1,650			—			1,650				6,379			853			7,232			—			7,232
Interest income		—			—			—			14			14				—			—			—			20			20
Interest expense		(25	)		(1	)		(26	)		(341	)		(367	)			(35	)		(1	)		(36	)		(469	)		(505	)
Interest expense-financing fees		—			2			2			(83	)		(81	)			—			2			2			(135	)		(133	)
Depreciation and amortization		1,787			496			2,283			26			2,309				2,535			709			3,244			38			3,282
Segment loss		(1,007	)		(1,992	)		(2,999	)		(3,064	)		(6,063	)
Segment profit (loss)																		2,977			(1,981	)		996			(4,716	)		(3,720	)
Expenditures for segment assets		331			2			333			—			333				334			41			375			—			375

⁽¹⁾Amounts reflect the activity for corporate headquarters and PF Medical ~~S.A.,~~ not included in the segment information.

11.	Escrow Release (Divestiture of Schreiber, Yonley and Associates, Inc. (“SYA”)

On August 4, 2015, the Company received $50,000 which represented the portion of the proceeds from the divestiture of the Company’s wholly-owned subsidiary, SYA, on July 29, 2014 which was placed in an escrow account to cover any potential claims which the purchaser of SYA may have made for indemnification for certain limited types of losses incurred by the purchaser for a period of one year following the closing of the sale of SYA. The $50,000 was previously recorded as restricted cash on the Company’s Consolidated Balance Sheets.

12.	Income Taxes

The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes.

The Company had income tax expenses of ~~$36,000~~$53,000 and ~~$71,000~~$30,000 from continuing operations for the three ~~and six~~ months ended ~~June~~September 30, 2015 and the corresponding period of 2014, respectively, and income tax expenses of ~~$30,000~~$124,000 and ~~$60,000 from continuing operations~~$90,000 for the ~~three and six~~nine months ended ~~June~~September 30, 2015 and the corresponding period of 2014, respectively. The Company’s effective tax rates were approximately ~~6.1%~~3.5% and ~~(5.9%~~1.3% for the three months ended September 30, 2015 and 2014, respectively, and 42.9% and (2.8%) for the ~~three and six~~nine months ended ~~June~~September 30, 2015 ~~respectively,~~ and ~~(1.5%) and (1.1%) for the three and six months ended June 30,~~ 2014, respectively. The Company has provided a full valuation allowance on its net deferred tax assets.

~~12.~~13.

Related Party Transaction ~~Party Transactions~~

As previously disclosed, Mr. John ~~Climaco.~~

~~On June 2, 2015,~~Climaco, who currently serves as a member of the Company’s Board of Directors, is also Executive Vice-President of PF Medical, the Company’s majority-owned Polish subsidiary. Mr. Climaco ~~was elected as the Executive Vice President~~is also a director of ~~Perma-Fix~~Digirad Corporation. On July 24, 2015 PF Medical and Digirad entered into a multi-year Tc-99 Supplier Agreement and a Subscription Agreement (see Note 7 – “Perma-Fix Medical S.A. (“PF Medical”)~~, a majority-owned Polish subsidiary~~ for further information of ~~the Company.~~this transaction with Digirad). Mr. Climaco ~~will receive an annual salary from PF Medical of $150,000. Mr. Climaco currently serves as a Director of the Company and a member of the Strategic Advisory Committee of the Board.~~

~~On October 17, 2014, the Company’s Compensation and Stock Option Committee and the Board, with Mr. Climaco abstaining, approved~~entered into a consulting agreement with ~~John Climaco. Pursuant to~~ the ~~consulting agreement, Mr. Climaco was responsible to, among other things:~~

●

~~Review the Company’s operations to restructure costs to render the Company more competitive;~~

●

~~Evaluate all functions, including but not limited to sales, marketing, accounting, operations, and executive management as well as cost structures for each facility;~~

●

~~Assist in the development of the Company’s strategy opportunity and other initiatives, including but not limited to the development of the Company’s medical isotope technology; and~~

●

~~Other assignments as determined by the Board.~~

~~Mr. Climaco was paid~~Company dated October 17, 2014 which provided for payment of approximately $22,000 per month ~~under the~~for his services of certain consulting ~~agreement, beginning September 2014.~~functions. This consulting agreement was terminated effective June 2, 2015, upon Mr. Climaco’s election as Executive Vice-President of PF Medical ~~discussed~~as noted above.

Mr. Climaco is also a director of Digirad Corporation. On July 24, 2015, PF Medical entered into a multi-year Tc-99m Supplier Agreement and a Subscription Agreement with Digirad Corporation (see “Note 13 - Subsequent Events” for further information regarding these Agreements).

P~~F Medical~~

Mr. Robert L. Ferguson, who the Company borrowed $3,000,000 pursuant to a Loan and Security Purchase Agreement and promissory note, dated August 2, 2013, and who also serves as an advisor to the Company’s Board, was also named as a member of its Supervisory Board of Directors As Executive Vice-President of PF Medical, ~~(see “Note 6 – Long Term Debt – Promissory Note and Installment Agreements” for further information of this loan).~~Mr. Climaco’s annual compensation has been set at $150,000.

~~13.~~

~~Subsequent Events~~

~~PF Medical~~

On July 24, 2015, the Company’s majority-owned Polish subsidiary, PF Medical and Digirad Corporation, a Delaware corporation (“Digirad”), Nasdaq: DRAD, entered into a multi-year Tc-99m Supplier Agreement (the “Supplier Agreement”) and a Series F Stock Subscription Agreement (the “Subscription Agreement”), (together, the “Digirad Agreements”). The Supplier Agreement is effective upon the completion of the Subscription Agreement. PF Medical was formed to develop and commercialize a new process to produce Tc-99m, the most widely used medical isotope in the world. Pursuant to the terms of the Digirad Agreements,Digirad purchased 71,429 shares of PF Medical’s restricted Series F Stock for an aggregate purchase price of $1,000,000. Under Polish law, issuance of shares requires approval of the shares by the Polish court which is expected to occur in the third quarter of 2015. In the event that the shares are not approved by the Polish court within 120 days from the date of payment by Digirad to PF Medical of the $1,000,000 purchase price on July 24, 2015, Perma-Fix Medical and Digirad have agreed that Perma-Fix Medical will return the $1,000,000 to Digirad and the Digirad Agreements shall terminate. The 71,429 share investment made by Digirad, when completed, will constitute approximately 5.4% of the outstanding common shares of Perma-Fix Medical. Upon issuance of the 71,429 shares to Digirad, the Company’s ownership interest in Perma-Fix Medical would be diluted from approximately 64.0% to approximately 60.5%. The Supplier Agreement provides, among other things, that upon PF Medical’s commercialization of certain Tc99m generators, Digirad will purchase agreed upon quantities of Tc-99m for its nuclear imaging operations either directly or in conjunction with its preferred nuclear pharmacy supplier and Perma-Fix Medical will supply Digirad, or its preferred nuclear pharmacy supplier, with Tc-99m at a preferred pricing, subject to certain conditions.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking Statements

Certain statements contained within this report may be deemed "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, the "Private Securities Litigation Reform Act of 1995"). All statements in this report other than a statement of historical fact are forward-looking statements that are subject to known and unknown risks, uncertainties and other factors, which could cause actual results and performance of the Company to differ materially from such statements. The words "believe," "expect," "anticipate," "intend," "will," and similar expressions identify forward-looking statements. Forward-looking statements contained herein relate to, among other things,

●	demand for our services;
●	reductions in the level of government funding in future years;
●	expect to meet our quarterly financial covenant requirements in ~~each of~~ the ~~remaining quarters~~final quarter of 2015;
●	ability to achieve profitability;
●	continuing demand for our services;
●	successfully implement our plan and generate positive cash flow in 2015;
●	~~expand~~continue to focus on expansion into both commercial and international markets to increase ~~revenues;~~revenues and expect to continue into 2016;
●	may not have liquidity to repay debt if our lender accelerates payment of our borrowings;
●	our cash flows from operations and our available liquidity from our Credit Facility are sufficient to service our obligations;
●

~~ability to continue under existing contracts that we have with the federal government (directly or indirectly as a subcontractor);~~

●	manner in which the government will be required to spend funding to remediate federal sites;
●	reducing operating costs to bring them in line with revenue level, when necessary;
●	~~receive~~PF Medical receiving remaining proceeds for the stock subscription receivables by December 2015;
●	fund capital expenditures from cash from operations and/or financing;
●	official issuance of grant for the Generator Project by NCRD is expected to occur during the latter part of 2015;
●	subsidy grant is expected to be funded based on milestone completion of the Generator Project;
●	~~if needed, Perma-Fix~~PF Medical expects to fund any capital requirements in excess of the subsidy grant for the Generator Project allocated by NCRD through the sale of equity;
●	completion of sale of PFMI property is subject to completion of due diligence within 45 days of the Agreement;
●	fund the expenses to remediate these sites (PFSG, PFD, PFMI, and PFM) from funds generated internally;
●	compliance with environmental regulations;
●	potential effect of being a PRP;
●	~~approval of issuance of restricted Series F Stock by Polish court;~~
●	~~we could become a PRP at a remedial action site, which could have a material adverse effect;~~ and
●	ability to remediate material weakness in internal control over financial reporting.

While the Company believes the expectations reflected in such forward-looking statements are reasonable, it can give no assurance such expectations will prove to have been correct. There are a variety of factors, which could cause future outcomes to differ materially from those described in this report, including, but not limited to:

●	general economic conditions;
●	manner in which government will spend funding for remediation projects;
●	material reduction in revenues;
●	reduction in levels of government funding for remediation projects;
●	ability to meet PNC covenant requirements;
●	inability to collect in a timely manner a material amount of receivables;
●	increased competitive pressures;
●	inability to maintain and obtain required permits and approvals to conduct operations;
●	public not accepting our new technology;
●	inability to develop new and existing technologies in the conduct of operations;
●	inability to maintain and obtain closure and operating insurance requirements;
●	inability to retain or renew certain required permits;
●	discovery of additional contamination or expanded contamination at any of the sites or facilities leased or owned by us or our subsidiaries which would result in a material increase in remediation expenditures;
●	delays at our third party disposal site can extend collection of our receivables greater than twelve months;
●	refusal of third party disposal sites to accept our waste;
●	changes in federal, state and local laws and regulations, especially environmental laws and regulations, or in interpretation of such;
●	requirements to obtain permits for treatment, storage and disposal activities or licensing requirements to handle low level radioactive materials are limited or lessened;
●	potential increases in equipment, maintenance, operating or labor costs;
●	management retention and development;
●	financial valuation of intangible assets is substantially more/less than expected;
●	the requirement to use internally generated funds for purposes not presently anticipated;
●	inability to continue to be profitable on an annualized basis;
●	inability of the Company to maintain the listing of its Common Stock on the NASDAQ;
●	termination or renegotiation of contracts with federal agencies or subcontracts involving federal agencies;
●	reduction in amount of waste delivered to the Company under the contracts or subcontracts;
●	federal government’s inability or failure to provide necessary funding to remediate contaminated federal sites;
●	disposal expense accrual could prove to be inadequate in the event the waste requires re-treatment;
●	inability to raise capital on commercially reasonable terms;
●	inability to increase profitable revenue; and
●	Risk Factors and other factors set forth in “Special Note Regarding Forward-Looking Statements” contained in the Company’s 2014 Form 10-K and Form 10-Q for the ~~quarter~~quarters ended March 31, 2015 and June 30, 2015.

The Company undertakes no obligations to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

Overview

Revenue increased ~~$3,697,000~~$404,000 or ~~29.2%~~2.4% to ~~$16,354,000~~$17,309,000 for the three months ended ~~June~~September 30, 2015 from ~~$12,657,000~~$16,905,000 for the corresponding period of 2014. ~~Revenue from our Treatment Segment~~Services revenue increased ~~$1,691,000~~$2,243,000 or ~~18.0%~~53.4% primarily due to ~~higher waste volume. Services~~the increase in revenue ~~increased $2,006,000 or 61.5% primarily due to~~from a contract which was awarded to us in the second half of 2014 in the nuclear services area. Revenue from our Treatment Segment decreased $1,839,000 or 14.5% primarily due to lower revenue from lower averaged price waste. Gross profit ~~increased $2,475,000~~decreased $635,000 or ~~159.0%~~11.4% primarily due to the ~~increase~~reduced revenue in ~~revenue and reduction in fixed costs as we continue to streamline~~ our ~~expenses.~~Treatment Segment. Selling, General, and Administrative (“SG&A”) expenses ~~decreased $65,000~~increased $154,000 or ~~2.2%~~5.6% for the three months ended ~~June~~September 30, 2015 as compared to the corresponding period of 2014.

Business Environment, Outlook and Liquidity

The Company’s business is heavily dependent on services that we provide to governmental clients directly as the contractor or indirectly as a subcontractor. We believe demand for our services will continue to be subject to fluctuations due to a variety of factors beyond our control, including the current economic conditions and the manner in which the government will be required to spend funding to remediate federal sites. In addition, our governmental contracts and subcontracts relating to activities at governmental sites are generally subject to termination or renegotiation on 30 days notice at the government’s option. Significant reductions in the level of governmental funding or specifically mandated levels for different programs that are important to our business could have a material adverse impact on our business, financial position, results of operations and cash flows. The Company continues to focus on expansion into both commercial and international markets to increase revenues to offset the uncertainties of government spending in the USA. This ~~includes new services, new customers~~focus has resulted in an increase in revenue from commercial sources in 2015 and ~~increased~~is expected to continue into 2016. In addition, the Company remains focused on increasing its international market ~~share in our current markets. Although no assurances can be given, we believe we will be able to successfully implement this plan and generate positive cash flow for the remainder of 2015.~~share.

The Company’s cash flow requirements for the remainder of 2015 will consist primarily of general working capital needs, scheduled principal payments on our debt obligations, remediation projects and planned capital expenditures which we expect to fund from operations and our availability from our credit facility.

Results of Operations

The reporting of financial results and pertinent discussions are tailored to two reportable segments: The Treatment and Services Segments.

Three Months Ended

Six Months Ended

June 30,

June 30,

Consolidated (amounts in thousands)

2015

%

2014

%

2015

%

2014

%

Net revenues
$ 16,354 100.0 $ 12,657 100.0 $ 29,955 100.0 $ 23,201 100.0
Cost of goods sold
12,322 75.3 11,100 87.7 24,445 81.6 21,551 92.9
Gross profit
4,032 24.7 1,557 12.3 5,510 18.4 1,650 7.1
Selling, general and administrative
2,905 17.8 2,970 23.5 5,776 19.3 6,182 26.6
Impairment loss on goodwill
— — 380 3.0 — — 380 1.6
Research and development
514 3.1 317 2.5 918 3.1 687 3.0
Gain on disposal of property andequipment
— — (16 ) — — — (16 ) —
Income (loss) from operations
613 3.8 (2,094 ) (16.7 ) (1,184 ) (4.0 ) (5,583 ) (24.1 )
Interest income
11 — 6 — 20 — 14 —
Interest expense
(140 ) (.9 ) (214 ) (1.7 ) (267 ) (.9 ) (367 ) (1.5 )
Interest expense-financing fees
(56 ) (.3 ) (36 ) — (115 ) (.3 ) (81 ) (.3 )
Foreign currency loss
— — — — (4 ) — — —
Other
15 .1 7 — 15 — 14 —
Income (loss) from continuing operationsbefore taxes
443 2.7 (2,331 ) (18.4 ) (1,535 ) (5.2 ) (6,003 ) (25.9 )
Income tax expense
36 .2 30 .2 71 .2 60 .2
Income (loss) from continuing operations
$ 407 2.5 $ (2,361 ) (18.6 ) $ (1,606 ) (5.4 ) $ (6,063 ) (26.1 )

~~Summary – Three and Six Months Ended June 30, 2015 and 2014~~

	Three Months Ended												Nine Months Ended
	September 30,												September 30,
Consolidated (amounts in thousands)	2015			%			2014			%			2015			%			2014			%
Net revenues	$	17,309			100.0		$	16,905			100.0		$	47,264			100.0		$	40,106			100.0
Cost of goods sold		12,363			71.4			11,324			67.0			36,809			77.9			32,874			82.0
Gross profit		4,946			28.6			5,581			33.0			10,455			22.1			7,232			18.0
Selling, general and administrative		2,887			16.7			2,733			16.2			8,663			18.3			8,916			22.2
Research and development		583			3.4			253			1.4			1,500			3.1			941			2.4
Impairment loss on goodwill		-			-			-			-			-			-			380			.9
Gain on disposal of property andequipment		(23	)		(.1	)		(25	)		(.1	)		(23	)		-			(41	)		(.1	)
Income (loss) from operations		1,499			8.6			2,620			15.5			315			.7			(2,964	)		(7.4	)
Interest income		16			-			7			-			36			-			20			-
Interest expense		(124	)		(.7	)		(138	)		(.8	)		(390	)		(.8	)		(505	)		(1.3	)
Interest expense-financing fees		(56	)		(.2	)		(52	)		(.3	)		(171	)		(.3	)		(133	)		(.3	)
Foreign currency loss		(2	)		-			-			-			(7	)		-			-			-
Other		4			-			(63	)		(.4	)		19			-			(48	)		(.1	)
Income (loss) from continuing operationsbefore taxes		1,337			7.7			2,374			14.0			(198	)		(.4	)		(3,630	)		(9.1	)
Income tax expense		53			.3			30			.1			124			.3			90			.2
Income (loss) from continuing operations	$	1,284			7.4		$	2,344			13.9		$	(322	)		(.7	)	$	(3,720	)		(9.3	)

Summary – Three and Nine Months Ended September 30, 2015 and 2014

Consolidated revenues increased ~~$3,697,000~~$404,000 for the three months ended ~~June~~September 30, 2015, compared to the three months ended ~~June~~September 30, 2014, as follows:

(In thousands)	2015		% Revenue		2014		% Revenue		Change			% Change			2015		% Revenue		2014		% Revenue		Change			% Change
Treatment
Government waste	$	8,322		50.9	$	6,180		48.8	$	2,142			34.7		$	8,193		47.3	$	10,011		59.2	$	(1,818	)		(18.2	)
Hazardous/non-hazardous		1,276		7.8		1,158		9.1		118			10.2			1,044		6.0		1,085		6.4		(41	)		(3.8	)
Other nuclear waste		1,489		9.1		2,058		16.3		(569	)		(27.6	)		1,629		9.5		1,609		9.6		20			1.2
Total		11,087		67.8		9,396		74.2		1,691			18.0			10,866		62.8		12,705		75.2		(1,839	)		(14.5	)

Services
Nuclear services		4,591		28.1		1,545		12.2		3,046			197.2			6,001		34.6		3,306		19.5		2,695			81.5
Technical services		676		4.1		1,716		13.6		(1,040	)		(60.6	)		442		2.6		894		5.3		(452	)		(50.6	)
Total		5,267		32.2		3,261		25.8		2,006			61.5			6,443		37.2		4,200		24.8		2,243			53.4

Total	$	16,354		100.0	$	12,657		100.0	$	3,697			29.2		$	17,309		100.0	$	16,905		100.0	$	404			2.4

Net Revenue

Treatment Segment revenue ~~increased $1,691,000~~decreased $1,839,000 or ~~18.0%~~14.5% for the three months ended ~~June~~September 30, 2015 over the same period in 2014. The revenue ~~increase~~decrease was primarily due to ~~higher~~lower revenue generated from government clients of approximately ~~$2,142,000~~$1,818,000 or ~~34.7% due to higher waste volume. Other nuclear revenue decreased approximately $569,000 primarily~~18.2% due to lower ~~waste volume.~~averaged price waste. Services Segment revenue increased ~~$2,006,000~~$2,243,000 or ~~61.5%~~53.4% in the three months ended ~~June~~September 30, 2015 ~~from~~compared to the corresponding period of 2014 primarily as a result of increased revenue generated from the nuclear services area from a certain contract which was awarded to us in the latter second half of 2014. ~~Revenue generated~~The increase in revenue from this contract for the third quarter of 2015 as compared to the corresponding period of 2014 was approximately ~~$2,900,000 in the second quarter of 2015.~~$2,400,000. The decrease in revenue in the technical services area was primarily due to the divestiture of Schreiber, Yonley & Associates, Inc. (“SYA”) subsidiary in July 2014, which generated revenues of approximately ~~$834,000~~$273,000 in the ~~second~~third quarter of 2014.

Consolidated revenues increased ~~$6,754,000~~$7,158,000 for the ~~six~~nine months ended ~~June~~September 30, 2015, as compared to the ~~six~~nine months ended ~~June~~September 30, 2014, as follows:

(In thousands)	2015		% Revenue		2014		% Revenue		Change			% Change			2015		% Revenue		2014		% Revenue		Change			% Change
Treatment
Government waste	$	15,376		51.3	$	10,312		44.4	$	5,064			49.1		$	23,613		50.0	$	20,323		50.7	$	3,290			16.2
Hazardous/non-hazardous		2,273		7.6		2,085		9.0		188			9.0			3,317		7.0		3,170		7.9		147			4.6
Other nuclear waste		3,187		10.7		4,671		20.2		(1,484	)		(31.8	)		4,772		10.1		6,280		15.6		(1,508	)		(24.0	)
Total		20,836		69.6		17,068		73.6		3,768			22.1			31,702		67.1		29,773		74.2		1,929			6.5

Services
Nuclear services		7,670		25.6		3,029		13.0		4,641			153.2			13,670		28.9		6,384		15.9		7,286			114.1
Technical services		1,449		4.8		3,104		13.4		(1,655	)		(53.3	)		1,892		4.0		3,949		9.9		(2,057	)		(52.1	)
Total		9,119		30.4		6,133		26.4		2,986			48.7			15,562		32.9		10,333		25.8		5,229			50.6

Total	$	29,955		100.0	$	23,201		100.0	$	6,754			29.1		$	47,264		100.0	$	40,106		100.0	$	7,158			17.8

Net Revenue

Treatment Segment revenue increased ~~$3,768,000~~$1,929,000 or ~~22.1%~~6.5% for the ~~six~~nine months ended ~~June~~September 30, 2015 over the same period in 2014. The revenue increase was primarily due to higher revenue generated from government clients of approximately ~~$5,064,000~~$3,290,000 or ~~49.1%~~16.2% due to higher waste volume. Other nuclear revenue decreased approximately ~~$1,484,000~~$1,508,000 primarily due to lower waste volume. Services Segment revenue increased ~~$2,986,000~~$5,229,000 or ~~48.7%~~50.6% in the ~~six~~nine months ended ~~June~~September 30, 2015 ~~from~~compared to the corresponding period of 2014 primarily as a result of increased revenue generated from ~~the nuclear services area from~~ a certain contract ~~which was~~ awarded to us in the second half of ~~2014.~~2014 in the nuclear services area. Revenue generated from this contract was approximately ~~$4,800,000~~$8,572,000 in the first ~~six~~nine months of ~~2015.~~2015 as compared to approximately $1,391,000 for the corresponding period of 2014. The decrease in revenue in the technical services area was primarily due to the divestiture of the SYA subsidiary in July 2014, which generated revenues of approximately ~~$1,614,000~~$1,888,000 in the first ~~six~~nine months of 2014.

Cost of Goods Sold

Cost of goods sold increased ~~$1,222,000~~$1,039,000 for the quarter ended ~~June~~September 30, 2015, as compared to the quarter ended ~~June~~September 30, 2014, as follows:

			%				%							%				%
(In thousands)	2015		Revenue		2014		Revenue		Change			2015		Revenue		2014		Revenue		Change
Treatment	$	7,752		69.9	$	8,071		85.9	$	(319	)	$	7,170		66.0	$	7,762		61.1	$	(592	)
Services		4,570		86.8		3,029		92.9		1,541			5,193		80.6		3,562		84.8		1,631
Total	$	12,322		75.3	$	11,100		87.7	$	1,222		$	12,363		71.4	$	11,324		67.0	$	1,039

Cost of goods sold for the Treatment Segment decreased by ~~$319,000~~$592,000 or approximately ~~4.0%~~7.6% primarily due to ~~revenue mix and reduction in certain of our fixed costs.~~reduced revenue. We incurred lower disposal, transportation, lab, material and supplies, and outside services costs totaling approximately $650,000. The lower costs were partially offset by higher maintenance costs for certain buildings and equipment of approximately $50,000 and higher 401(k) matching expenses in the amount of approximately $33,000 as we re-established our matching program effective January 1, 2015. Services Segment cost of goods sold increased $1,631,000 or 45.8% primarily due to the increase in revenue as discussed above. The increases were primarily in disposal/transportation/lab costs totaling approximately $837,000 resulting from waste shipped off-site in connection with certain projects, with the remaining increases in labor, payroll-related and travel expenses totaling approximately $721,000 and material and supplies of $68,000. Included within cost of goods sold is depreciation and amortization expense of $879,000 and $902,000 for the three months ended September 30, 2015, and 2014, respectively.

Cost of goods sold increased $3,935,000 for the nine months ended September 30, 2015, as compared to the nine months ended September 30, 2014, as follows:

			%				%
(In thousands)	2015		Revenue		2014		Revenue		Change
Treatment	$	23,437		73.9	$	23,394		78.6	$	43
Services		13,372		85.9		9,480		91.7		3,892
Total	$	36,809		77.9	$	32,874		82.0	$	3,935

Cost of goods sold for the Treatment Segment increased by $43,000 or 0.2% primarily due to higher revenue. We incurred higher transportation, disposal, material and supplies, lab, and outside services costs totaling approximately ~~$260,000.~~$255,000. Our overall fixed costs were lower by approximately ~~$75,000. Total salaries~~$168,000. We incurred a significant reduction in depreciation expense of approximately $205,000 as certain fixed assets became fully depreciated in June 2014. Salaries and ~~payroll related~~payroll-related expenses were lower by approximately ~~$127,000 from~~$295,000 due to lower headcount and lower healthcare costs which ~~were~~was partially offset by higher 401(k) matching expenses in the amount of approximately ~~$32,000~~$95,000 as we re-established our matching program effective January 1, 2015. ~~Total~~In addition, general ~~expenses~~costs were lower by approximately ~~$11,000 in~~$25,000 over various categories as we continue to streamline our costs. ~~Depreciation expense was lower by $56,000 as certain fixed assets became fully depreciated in June 2014.~~ These lower fixed costs were offset by higher maintenance costs of approximately ~~$132,000 due to~~$269,000 resulting from maintenance of certain buildings and equipment. Services Segment cost of goods sold increased ~~$1,541,000~~$3,892,000 or ~~50.9%~~41.1% primarily due to the increase in revenue as discussed ~~above. The increase was~~above, with increases primarily in ~~salaries and~~labor, payroll related and travel expenses totaling approximately ~~$820,000,~~$2,178,000, with the remaining ~~increase~~increases in material and supplies of $662,000 and disposal/transportation/lab costs totaling approximately ~~$430,000 and increase in disposal costs of approximately $300,000 due to~~$1,160,000 resulting from waste shipped ~~offsite~~off-site in connection with certain projects. Included within cost of goods sold is depreciation and amortization expense of ~~$893,000~~$2,684,000 and ~~$962,000~~$2,922,000 for the ~~three~~nine months ended ~~June~~September 30, 2015, and 2014, respectively.

~~Cost of goods sold increased $2,894,000 for the six months ended June 30, 2015, as compared to the six months ended June 30, 2014, as follows:~~

%

%

(In thousands)

2015

Revenue

2014

Revenue

Change

Treatment
$ 16,266 78.1 $ 15,633 91.6 $ 633
Services
8,179 89.7 5,918 96.5 2,261
Total
$ 24,445 81.6 $ 21,551 92.9 $ 2,894

Cost of goods sold for the Treatment Segment increased by $633,000 or 4.0% primarily due to higher revenue. We incurred higher disposal, transportation, lab, and material and supplies costs totaling approximately $826,000. Our overall fixed costs were lower by approximately $233,000. We incurred a significant reduction in depreciation expense of approximately $186,000 as certain fixed assets became fully depreciated in June 2014. Salaries and payroll related expenses were lower by approximately $168,000 due to lower headcount and lower healthcare costs which were partially offset by higher 401(k) matching expenses in the amount of approximately $63,000 as we re-established our matching program effective January 1, 2015. General expenses were lower by approximately $68,000 in various categories as we continue our effort in streamlining our costs. These lower fixed costs were offset by higher maintenance costs of approximately $220,000 due to maintenance of certain buildings and equipment. Services Segment cost of goods sold increased $2,261,000 or 38.2% primarily due to the increase in revenue as discussed above, with increases primarily in salaries and payroll related and travel expenses totaling approximately $1,577,000, with the remaining increases in material and supplies of $595,000 and disposal costs of $300,000 (as discussed in the three months ended June 30, 2015 above). The increased cost was partially offset by lower outside services expenses, resulting from fewer subcontracting/consulting services, of approximately $120,000 and lower general expenses of $90,000 in various categories. Included within cost of goods sold is depreciation and amortization expense of $1,805,000 and $2,020,000 for the six months ended June 30, 2015, and 2014, respectively.

Gross Profit

Gross profit for the quarter ended ~~June~~September 30, 2015, ~~increased $2,475,000~~decreased $635,000 over ~~the same period in~~ 2014, as follows:

			%				%						%				%
(In thousands)	2015		Revenue		2014		Revenue		Change		2015		Revenue		2014		Revenue		Change
Treatment	$	3,335		30.1	$	1,325		14.1	$	2,010	$	3,696		34.0	$	4,943		38.9	$	(1,247	)
Services		697		13.2		232		7.1		465		1,250		19.4		638		15.2		612
Total	$	4,032		24.7	$	1,557		12.3	$	2,475	$	4,946		28.6	$	5,581		33.0	$	(635	)

The ~~increase in gross profit was primarily due to the increase~~reduction in gross profit in the Treatment ~~Segment. Treatment~~ Segment ~~gross profit increased $2,010,000~~of approximately $1,247,000 or ~~151.7%~~25.2% and the reduction in gross margin ~~increased~~from 38.9% to ~~30.1% from 14.1%~~34.0% were primarily due to ~~increased~~reduced revenue from ~~higher waste volume.~~lower averaged price waste. In the Services Segment, the increases in gross profit of ~~$465,000~~$612,000 and gross margin of approximately ~~6.1%~~4.2% was primarily due to the increase in revenue as discussed above. In addition, infixed costs remained relatively constant which positively impacted the ~~second quarter of 2014, we completed a reduction in work force which reduced headcount~~increase in our ~~effort to bring our cost structure in line with our revenue volume.~~gross margin.

Gross profit for the ~~six~~nine months ended ~~June~~September 30, 2015, increased ~~$3,860,000~~$3,223,000 over 2014, as follows:

			%				%						%				%
(In thousands)	2015		Revenue		2014		Revenue		Change		2015		Revenue		2014		Revenue		Change
Treatment	$	4,570		21.9	$	1,435		8.4	$	3,135	$	8,265		26.1	$	6,379		21.4	$	1,886
Services		940		10.3		215		3.5		725		2,190		14.1		853		8.3		1,337
Total	$	5,510		18.4	$	1,650		7.1	$	3,860	$	10,455		22.1	$	7,232		18.0	$	3,223

~~The increase in~~Treatment Segment gross profit ~~was~~increased $1,886,000 or 29.6% and gross margin increased to 26.1% from 21.4% primarily due to the increase in ~~gross profit in the Treatment Segment. Treatment Segment gross profit~~revenue from increased ~~$3,135,000 or 218.5%~~waste volume and ~~gross margin increased to 21.9% from 8.4% primarily due to~~ a reduction of certain fixed costs as discussed ~~above and increased revenue from higher waste volume.~~above. In the Services Segment, the increases in gross profit of ~~$725,000~~$1,337,000 and gross margin were primarily due to the increase in revenue as discussed above. In addition, in the second quarter of 2014, we completed a reduction in work force which reduced headcount in our effort to bring our cost structure in line with our revenue.

Selling, General and Administrative

Selling, general and administrative ("SG&A")expenses ~~decreased $65,000~~increased $154,000 for the three months ended ~~June~~September 30, 2015, as compared to the corresponding period for 2014, as follows:

														%				%
(In thousands)	2015		% Revenue		2014		% Revenue		Change			2015		Revenue		2014		Revenue		Change
Administrative	$	1,277		—	$	1,154		—	$	123		$	1,198		—	$	1,278		—	$	(80	)
Treatment		976		8.8		995		10.6		(19	)		931		8.6		866		6.8		65
Services		652		12.4		821		25.2		(169	)		758		11.8		589		14.0		169
Total	$	2,905		17.8	$	2,970		23.5	$	(65	)	$	2,887		16.7	$	2,733		16.2	$	154

Administrative SG&A was lower primarily due to lower salaries and payroll related expenses of approximately $54,000 and lower general expenses of approximately $38,000 in various categories. The lower costs were partially offset by higher travel expenses of $10,000. The increase in Treatment SG&A was primarily due to higher trade show costs by approximately $56,000 with the remaining increase from higher travel expenses. Services Segment SG&A was higher primarily due to higher legal/business consulting costs of approximately $67,000, higher salaries and payroll related expenses by approximately $55,000 from increased sales force, higher travel expenses by $25,000, and higher general expenses by $54,000 in various other categories. These higher costs were partially offset by lower amortization expenses of $32,000 as certain amortizable intangible assets became fully amortized in July 2014. Included in SG&A expenses is depreciation and amortization expense of $33,000 and $71,000 for the three months ended September 30, 2015, and 2014, respectively.

SG&Aexpenses decreased $253,000 for the nine months ended September 30, 2015, as compared to the corresponding period for 2014, as follows:

			%				%
(In thousands)	2015		Revenue		2014		Revenue		Change
Administrative	$	3,849		—	$	3,691		—	$	158
Treatment		2,864		9.0		2,876		9.7		(12	)
Services		1,950		12.5		2,349		22.7		(399	)
Total	$	8,663		18.3	$	8,916		22.2	$	(253	)

The decrease in total SG&A was primarily due to lower SG&A in the Services Segment. Salaries and payroll related expenses were lower by approximately $151,000 from lower headcount which was attributed to a reduction in workforce which occurred in May 2014. Amortization expense was lower by $40,000 due to certain amortizable intangible assets which became fully amortized in July 2014. General expenses were lower in various categories totaling approximately $16,000. These lower costs were offset by higher outside services of approximately $36,000 due to more legal/business matters. The small reduction in Treatment SG&A was primarily due to lower payroll related and healthcare expenses. The increase in administrative SG&A was primarily the result of higher outside services expenses by approximately $117,000 resulting from more consulting/business/legal matters, higher travel expenses by $20,000, and higher general expenses by approximately $33,000. These higher costs were partially offset by lower salaries and payroll related expenses totaling approximately $45,000. Included in SG&A expenses is depreciation and amortization expense of $50,000 and $100,000 for the three months ended June 30, 2015, and 2014, respectively.

~~SG&~~A~~expenses decreased $406,000 for the six months ended June 30, 2015, as compared to the corresponding period for 2014, as follows:~~

(In thousands)

2015

%
Revenue

2014

%
Revenue

Change

Administrative
$ 2,650 — $ 2,412 — $ 238
Treatment
1,933 9.3 2,010 11.8 (77 )
Services
1,193 13.1 1,760 28.7 (567 )
Total
$ 5,776 19.3 $ 6,182 26.6 $ (406 )

~~The decrease in total SG&A was primarily due to lower SG&A in the Services Segment. Salaries and payroll related expenses were lower by approximately $442,000~~$387,000 from lower headcount which was attributed to a reduction in workforce which occurred in May 2014. Amortization expense was lower by approximately ~~$80,000~~$112,000 due to certain amortizable intangible assets which became fully amortized in July ~~2014 and general~~2014. The lower costs were partially offset by higher legal/business consulting expenses ~~were lower in various categories~~ totaling approximately ~~$62,000.~~$70,000. Treatment SG&A was lower primarily due to lower salaries and payroll related expenses ~~from~~totaling approximately $109,000. The lower ~~headcount.~~costs were mostly offset by higher travel expenses of approximately $29,000 and higher trade show costs by approximately $65,000. The increase in administrative SG&A was primarily the result of higher outside services expenses by approximately ~~$245,000~~$247,000 resulting from more consulting/business/legal matters and higher travel expenses by ~~$26,000, and higher general expenses by $39,000.~~$36,000. Stock based compensation expenses were also higher by approximately ~~$65,000.~~$66,000. Our stock based compensation expenses for the first ~~six~~nine months of 2014 included a reduction in expenses of approximately $54,000 recorded in the first quarter of 2014 resulting from the forfeiture of options by our previous Chief Operating Officer (“COO”), who voluntarily resigned from the Company effective March 28, 2014.These higher costs were partially offset by lower salaries and payroll related expenses totaling approximately ~~$135,000~~$191,000 from lower headcount. Included in SG&A expenses is depreciation and amortization expense of ~~$104,000~~$137,000 and ~~$200,000~~$270,000 for the ~~six~~nine months ended ~~June~~September 30, 2015 and 2014, respectively.

Research and Development (“R&D”)

Research and development costs increased ~~$197,000~~$330,000 and ~~$231,000~~$559,000 for the three and ~~six~~nine months ended ~~June~~September 30, 2015, respectively, as compared to the corresponding periods of 2014. Research and development costs consist primarily of employee salaries and benefits, laboratory costs, third party fees, and other related costs associated with the development of new technologies to increase company offerings and technological enhancement of new potential waste treatment processes. Our R&D costs included approximately ~~$432,000~~$527,000 and ~~$184,000~~$229,000 for the three months ended ~~June~~September 30, 2015 and the corresponding period of 2014, respectively, and approximately ~~$827,000~~$1,354,000 and ~~$317,000~~$548,000 for the ~~six~~nine months ended ~~June~~September 30, 2015 and the corresponding period of 2014, respectively, for the R&D ofrelated to the medical isotope (Technetium-99 or “Tc-99m”) technology (see “Financial Activities” in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for further information of Perma-Fix Medical S.A (“PF ~~Medical S.A.~~Medical”), our majority-owned Polish subsidiary whose primary purpose is the R&D of technology for the Medical Isotope project). Included in R&D expense is depreciation expense of ~~$36,000~~$0 and ~~$89,000~~$90,000 for the three and ~~six~~nine months ended ~~June~~September 30, 2014, respectively. No depreciation expense was included in R&D expense for the three and ~~six~~nine months ended ~~June~~September 30, ~~2015.~~2015 due to fully depreciated equipment in the second quarter of 2014.

Interest Expense

Interest expense decreased approximately ~~$74,000 and $100,000~~$14,000 for the three ~~and six~~ months ended ~~June~~September 30, 2015, ~~respectively,~~ as compared to the corresponding period of 2014 primarily due to lower interest from our declining Term Loan ~~balance. Also,~~balance and lower interest from the declining $3,000,000 loan dated August 2, 2013. The lower interest expense was partially offset by higher interest expense resulting from higher average Revolver loan balance over the period. Interest expense decreased $115,000 for the nine months ended September 30, 2015, as compared to the corresponding period of 2014 primarily due to the same reasons as discussed above. In addition, interest expense was lower infor the nine months ended September 30, 2015 as compared to the corresponding period of 2014 as interest expense for the ~~three and six~~nine months ended ~~June~~September 30, 2014 included approximately $37,000 in loss on debt modification (recorded in accordance with ASC 470-50, “Debt – Modification and Extinguishment”) incurred as a result of an amended loan agreement that we entered into with our lender on April 14, 2014, which reduced our Revolving Credit line from $18,000,000 to $12,000,000.

Interest Expense- Financing Fees

Interest expense-financing fees increased approximately ~~$20,000~~$4,000 and ~~$34,000~~$38,000 for the three and ~~six~~nine months ended ~~June~~September 30, 2015, respectively, as compared to the corresponding period of 2014. The increase was primarily due to anthe increase in monthly amortized financing fees associated with amendments to our credit facility that we entered into with our lender inon April 14, 2014 and July 25, 2014.

Discontinued Operations and Divestitures

The Company’s discontinued operations consist of subsidiaries included in our Industrial Segment: (1) subsidiaries divested in 2011 and prior, (2) two previously closed locations, and (3) our Perma-Fix of South Georgia, Inc. (“PFSG”) facility. On August 14, 2013, our PFSG facility incurred fire damage which left it non-operational. In 2014, the Company elected not to rebuild the PFSG facility. The Company carried general liability, pollution, property and business interruption, and workers compensation insurance with a maximum deductible of approximately $300,000. On June 20, 2014, the Company entered into a settlement agreement and release with one of its insurance carriers resulting in receipt of approximately $3,850,000 in insurance settlement proceeds on June 30, 2014, which was used ~~to pay down the Company’s Revolving Credit.~~for working capital purposes.

On May 11, 2015, PFSG received a Notice of Violation and proposed Consent Order (“CO”) from the Georgia Department of Natural Resources Environmental Protection Division (“GAEPD”), which alleged certain violations of Georgia ~~Rules for Hazardous Waste Management~~hazardous waste management regulations and ~~the~~ PFSG ~~Hazardous Waste Permit.~~hazardous waste management permit. The proposed CO also established the process for formerly closing the PFSG hazardous waste management facilities, should PFSG elect to do ~~so.~~so; and proposed the assessment of a civil penalty. As previously disclosed, the final terms of the CO, including a $201,200 civil penalty, were executed on July 1, 2015. The ~~CO requests payment of $201,200 as~~civil penalty ~~for these alleged violations which~~ was paid by the Company and recorded in the three months ended June 30, 2015. ~~Pursuant to~~On August 28, 2015, the ~~CO, PFSG shall have 60 days from July 1, 2015 to provide notification of final closure of the entire facility or~~Company notified GAEPD its intent to ~~resume hazardous waste management operations;~~close the PFSG facility; and ~~90 days from July 1,~~on September 29, 2015, ~~to submit~~the Company submitted a ~~post closure plan in~~draft Post-Closure Plan for review and approval by the event PFSG decides to proceed with final closure of the facility.The Company has begun initiating full closure requirements of the facility which will include submittal of a post closure plan to be approved by GAEPD. ~~As a result, PFSG is no longer classified as held for sale.~~

On June 4, 2015, the ~~Company~~Perma-Fix of Michigan, Inc. (“PFMI”) entered into a letter of intent (“LOI”) to sell the property ~~which our Perma-Fix of Michigan, Inc. (“PFMI”)~~PFMI formerly operated on for a sale price of approximately $450,000. PFMI is a closed location. ~~The sale of the property at PFMI is subject to execution of a purchase agreement and completion of due diligence within 90 days of the LOI.~~ As required by ASC 360, the Company concluded that tangible asset impairment existed for PFMI ~~as of June 30, 2015~~ and recorded approximately $150,000 in asset impairment ~~charge.~~charge in the second quarter of 2015. On September 29, 2015, PFMI entered into a Purchase Agreement (the “Agreement”) for the sale of the property for a sale price of $450,000, which is subject to completion of a due diligence within 45 days of the Agreement. Upon execution of the Agreement, PFMI received $20,000 deposit which is being held in an escrow account (recorded as restricted cash within discontinued operations). Upon closing of the transaction, PFMI is to receive an additional $55,000 in cash in addition to the $20,000 held in escrow and PFMI and the seller will execute a Land Contract (“Contract”) which will provide for, among other things, the remaining balance of the sales price of $375,000 to be paid by the seller in 60 equal monthly installment payments of approximately $7,250, due on or before the 15^th of each month immediately following the execution of the Contract. PFMI retains legal title to the property until the buyer fulfills the obligations under the Contract.

Our discontinued operations had no revenue for the three and ~~six~~nine months ended ~~June~~September 30, 2015 and the corresponding period of 2014. We had net losses of ~~$713,000~~$377,000 and ~~$936,000~~$1,313,000 for our discontinued operations for the three and ~~six~~nine months ended ~~June~~September 30, 2015, respectively. Our ~~losses~~loss for the ~~three and six~~nine months ended ~~June~~September 30, 2015 included the civil penalty recorded during the second quarter of 2015 for our PFSG facility and the asset impairment charge recorded during the second quarter of 2015 for our PFMI facility as discussed above. We had net loss of $473,000 and net income of ~~$2,372,000 and $2,105,000~~$1,633,000 for our discontinued operations for the three and ~~six~~nine months ended ~~June~~September 30, 2014, respectively. Our net income ~~from~~for our discontinued operations for the ~~three and six~~nine months ended ~~June~~September 30, 2014, included a gain on insurance settlement of approximately ~~$3,541,000~~$3,530,000 and asset impairment ~~charges~~charge of ~~$685,000~~$723,000 (of which $38,000 was recorded during the third quarter of 2014) for our PFSG subsidiary.

Liquidity and Capital Resources

Our cash flow requirements during the ~~six~~nine months ended ~~June~~September 30, 2015 were primarily financed by our operations and Credit Facility. Our ability to achieve and maintain profitability is dependent upon our ability to generate profitable revenues through successfully implementing our business plans, which includes ~~expansion~~our continued focus into both commercial and international markets to increase revenues to offset the uncertainties of government spending in the United States of America. We continue to explore all sources of increasing revenue. We are continually reviewing operating costs and are committed to further reducing operating costs to bring them in line with revenue levels, when necessary. Our capital requirements consist of general working capital needs, scheduled principal payments on our debt obligations, remediation projects and planned capital expenditures. Although there are no assurances, we believe that our cash flows from operations and our ~~available liquidity~~availability from our Credit Facility are sufficient to fund our operations.

The following table reflects the cash flow activity for the first ~~six~~nine months of 2015:

(In thousands)	2015			2015
Cash used in operating activities of continuing operations	$	(1,273	)
Cash provided by operating activities of continuing operations				$	1,484
Cash used in operating activities of discontinued operations		(798	)		(1,233	)
Cash used in investing activities of continuing operations		(282	)		(291	)
Cash used in financing activities of continuing operations		(223	)		(1,579	)
Effect of exchange rate changes on cash		(63	)		(63	)
Decrease in cash	$	(2,639	)	$	(1,682	)

As of ~~June~~September 30, 2015, we were in a net borrowing position (Revolving Credit Facility). The cash balance at ~~June~~September 30, 2015, is primarily cash received from sale of certain equity by our majority-owned Polish subsidiary, ~~Perma-Fix~~PF Medical ~~S.A.~~ (which is not a credit party under our Amended Loan Agreement), and minor petty cash and local account balances used for miscellaneous services and supplies at our remaining subsidiaries.

Operating Activities

Accounts Receivable, net of allowances for doubtful accounts, totaled ~~$9,615,000~~$8,462,000 at ~~June~~September 30, 2015, an increase of ~~$1,343,000~~approximately $190,000 from the December 31, 2014 balance of $8,272,000. The increase was primarily due to increased ~~revenue and timing of accounts receivable collections~~billings due to ~~the variety of payment terms provided to our customers.~~increased revenue which was partially offset by increased cash receipts.

Accounts Payable, totaled ~~$5,485,000~~$4,908,000 at ~~June~~September 30, 2015, ~~an increase~~a decrease of ~~$135,000~~$442,000 from the December 31, 2014 balance of $5,350,000. The ~~increase~~decrease was primarily ~~related~~due to ~~the increase in activity as evidenced by the increase in revenue. Also, we~~pay down of our accounts payables from cash generated from operations. We continue to manage payment terms with our vendors to maximize our cash position throughout all segments.

Accrued expenses as of September 30, 2015 totaled $5,528,000, an increase of $988,000 over the December 31, 2014 balance of $4,540,000. Accrued expenses are made up of accrued compensation, interest payable, insurance payable, certain tax accruals, and other miscellaneous accruals. The increase was primarily the result of the renewal of the Company’s general insurance policies in September 2015 which we finance over a one year period.

Disposal/transportation accrual as of ~~June~~September 30, 2015, totaled ~~$1,410,000,~~$1,608,000, a decrease of ~~$325,000~~$129,000 over the December 31, 2014 balance of $1,737,000. Our disposal accrual can vary based on revenue mix and the timing of waste shipments for final disposal. During the first ~~six~~nine months of 2015, we shipped more waste for disposal which is reflected in a lower inventory on-site as compared to year end 2014.

We had working capital of ~~$101,000~~$1,149,000 (which included working capital of our discontinued operations) as of ~~June~~September 30, 2015, as compared to working capital of $757,000 as of December 31, 2014. Our working capital was impacted by the proceeds received from the sale of equity by our majority-owned Polish subsidiary, PF Medical, on July 24, 2015 to Digirad Corporation (see “Financing Activities” in this section for further information of this transaction), and cash generated from our operations, offset by payments of certain of our current ~~liabilities from cash that we generated from operations.~~liabilities.

Financing Activities

We entered into an Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated October 31, 2011, (“Loan Agreement”), with PNC Bank, National Association (“PNC”), acting as agent and lender. The Loan Agreement, as amended (“Amended Loan Agreement”), provides us with the following Credit Facility: (a) up to $12,000,000 revolving credit facility (“Revolving Credit”), subject to the amount of borrowings based on a percentage of eligible receivables (as defined) and (b) a term loan (“Term Loan”) of $16,000,000, which requires monthly installments of approximately $190,000 (based on a seven-year amortization).

As of ~~June~~September 30, 2015, the availability under our revolving credit agreement was ~~$3,637,000,~~$4,284,000, based on our eligible receivables and ~~includes~~is net of an indefinite reduction of borrowing availability of $1,500,000. On July 28, 2014, we entered into an amendment to the Amended Loan Agreement which among other things, authorized us to use the $3,850,000 insurance settlement proceeds received on June 30, 2014 by our Perma-Fix of South Georgia, Inc. (“PFSG”) subsidiary (which suffered a fire on August 14, 2013 and is included within our discontinued operations) for working capital purposes but placed an indefinite reduction on our borrowing availability by the $1,500,000 as discussed above.

Our Credit Facility with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our credit facility allowing our lender to immediately require the repayment of all outstanding debt under our Credit Facility and terminate all commitments to extend further credit. The following table illustrates the quarterly financial covenant requirements under our Credit Facility as of ~~June~~September 30, ~~2015.~~2015:

	Quarterly	1st Quarter	2nd Quarter	Quarterly	1st Quarter	2nd Quarter	3rd Quarter
(Dollars in thousands)	Requirement	Actual	Actual	Requirement	Actual	Actual	Actual
Senior Credit Facility
Fixed charge coverage ratio	1.15:1	2.79:1	1.70:1	1.15:1	2.79:1	1.70:1	1.42:1
Minimum tangible adjusted net worth	$30,000	$42,898	$42,694	$30,000	$42,898	$42,694	$44,653

We met our quarterly fixed charge coverage ratio and minimum tangible adjusted net worth requirements in each of the ~~first and second~~ quarters as of September 30, 2015 and we expect to meet these quarterly financial covenant requirements in ~~each of the remaining quarters~~final quarter of 2015; however, if we fail to meet any of these quarterly financial covenant requirements in ~~any~~the final quarter of ~~the remaining quarters in~~ 2015 and PNC does not waive the non-compliance or further revise our covenant so that we are in compliance, our lender could accelerate the repayment of borrowings under our Credit Facility. In the event that our lender accelerates the payment of our borrowings, we may not have sufficient liquidity to repay our debt under our credit facility and other indebtedness.

On February 12, 2013, we entered into an unsecured promissory note (“the new note”) with Timios National Corporation (“TNC”) in the principal amount of approximately $230,000 as a result of a settlement with TNC in connection with certain claims that we asserted against TNC for breach of certain representations and covenant subsequent to our acquisition of Safety & Ecology Corporation (“SEC”) from TNC on October 31, 2011. The new note was entered into as a result of the settlement in which a previously issued promissory note that we entered into with TNC as partial consideration of the purchase price of SEC was cancelled and terminated and replaced with the new note. We made the final payment of approximately $10,000 on this new note in January 2015.

On August 2, 2013, we completed a lending transaction with Messrs. Robert Ferguson (who serves as an advisor to the Company’s Board of Directors and is also a member of the Board of Directors of our majority-owned Polish Subsidiary, Perma-Fix Medical ~~S.A (“PF Medical”).)~~ and William Lampson (“collectively, the “Lenders”), whereby we borrowed from the Lenders the sum of $3,000,000 pursuant to the terms of a Loan and Security Purchase Agreement and promissory note (the “Loan”). The proceeds from the Loan were used for general working capital purposes. The promissory note is unsecured, with a term of three years with interest payable at a fixed interest rate of 2.99% per annum. The promissory note provides for monthly payments of accrued interest only during the first year of the Loan with the first interest payment due September 1, 2013, and monthly payments of $125,000 in principal plus accrued interest for the second and third year of the Loan. In connection with the above Loan, the Lenders entered into a Subordination Agreement dated August 2, 2013, with our Credit Facility lender, whereby the Lenders agreed to subordinate payment under the Loan, and agreed that the Loan will be junior in right of payment to the Credit Facility in the event of default or bankruptcy or other insolvency proceeding by us. As consideration for us receiving the Loan, we issued a Warrant to each Lender to purchase up to 35,000 shares of our Common Stock at an exercise price based on the closing price of our Common Stock at the closing of the transaction which was determined to be $2.23. The Warrants are exercisable six months from August 2, 2013 and expire on August 2, 2016. The fair value of the Warrants was estimated to be approximately $59,000 using the Black-Scholes option pricing model. As further consideration for the Loan, we also issued an aggregate 90,000 shares of our Common Stock, with each Lender receiving 45,000 shares. We determined the fair value of the 90,000 shares of Common Stock to be approximately $200,000 which was based on the closing price of the stock of $2.23 per share on August 2, 2013. The fair value of the Warrants and Common Stock and the related closing fees incurred from the transaction were recorded as a debt discount, which is being amortized using the effective interest method over the term of the loan as interest expense – financing ~~fees.~~fees in the accompanying Consolidated Statements of Operations.

During August 2014, PF Medical executed stock subscription agreements totaling approximately $2,357,000 for 250,000 shares of its Series E Common Stock to non-U.S. persons in an offshore private placement under Regulation S promulgated under the Securities Act of 1933, as amended (“Securities Act”). In connection with this transaction, ~~as of June 30, 2015,~~ PF Medical has received approximately $1,545,000 in proceeds, ~~(of~~of which approximately $67,000 was received in the first ~~quarter~~nine months of ~~2015)~~2015, for the 250,000 shares (before deduction for commissions and legal expenses relating to this offering of approximately $242,000). The $67,000 is being held in an escrow account as the proceeds will be used to pay for potential future expenses related to the medical isotope project. The Company has recorded the amount held in escrow as restricted cash on the accompanying Consolidated Balance ~~Sheet.~~Sheets. PF Medical expects to receive the remaining proceeds for the stock subscription receivables in the amount of approximately ~~$761,000~~$751,000 by December 2015. The remaining stock subscription receivables are offset against non-controlling interest. If PF Medical does not receive approximately ~~$599,000~~$591,000 of the remaining stock subscription receivables, which represents approximately 68,181 shares, PF Medical has the option to have the purchaser of such shares transfer all of its rights, title and interest in such shares to PF Medical or for PF Medical to be paid for the 68,161 shares with shares of another publicly traded company.

On April 30, 2015, PF Medical officially accepted a grant awarded by the National Centre for Research and Development (“NCRD”) in Poland to further develop and commercialize a novel prototype generator for the production of Tc-99m for use in cancer and cardiac imaging (“Generator Project”), subject to official issuance of the grant. The Generator Project is under the leadership and supervision of Perma-Fix Medical and consists of four additional entities from Poland (together known as the “Generator Project team”). NCRD’s subsidy grant for the Generator Project is approximately $2,800,000 and will be funded by NCRD over a four year period. If needed, PF Medical expects to fund any capital requirements in excess of the subsidy grant for the Generator Project allocated by NCRD through the sale of equity. Of the $2,800,000 subsidy grant allocation, PF Medical will directly receive approximately $800,000 over a four year period and the remaining amount will be allocated to other members of the Generator Project team to be used solely to support technology development and testing of the Generator Project. PF Medical is awaiting the official issuance of the grant from NCRD which is expected to occur during the latter part of 2015. The subsidy grant is expected to be funded based on milestone completion of the Generator Project.

On July 24, 2015, PF Medical and Digirad Corporation, a Delaware corporation (“Digirad”), Nasdaq: DRAD, entered into a multi-year Tc-99m Supplier Agreement (the “Supplier Agreement”) and a Series F Stock Subscription Agreement (the “Subscription Agreement”), (together, the “Digirad Agreements”). The Supplier Agreement isbecame effective upon the completion of the Subscription Agreement. PF Medical was formed to develop and commercialize a new process to produce Tc-99m, the most widely used medical isotope in the world. Pursuant to the terms of the Digirad Agreements,Digirad purchased, in a private placement and pursuant to Regulation S under the Securities Act, 71,429 shares of PF Medical’s restricted Series F Stock for an aggregate purchase price of ~~$1,000,000. Under Polish law,~~$1,000,000, which was received on July 24, 2015. The issuance ~~of shares requires approval~~ of the shares ~~by the Polish court which is expected to occur in the third quarter of 2015. In the event that the shares are not~~has been approved by the Polish ~~court within 120 days from~~authority. As of September 30, 2015, legal expenses incurred for this offering totaled approximately $29,000. The net proceeds of $971,000 in stock subscription were recorded as non-controlling interest on the date of payment by Digirad to PF Medical of the $1,000,000 purchase price on July 24, 2015, Perma-Fix Medical and Digirad have agreed that Perma-Fix Medical will return the $1,000,000 to Digirad and the Digirad Agreements shall terminate.accompanying Consolidated Balance Sheets. The 71,429 share investment made by Digirad ~~when completed, will constitute~~constituted approximately 5.4% of the outstanding common shares of ~~Perma-Fix~~PF Medical. ~~Upon issuance~~As a result of ~~the 71,429 shares to Digirad,~~this transaction, the Company’s ownership interest in ~~Perma-Fix~~PF Medical ~~would be~~ diluted from approximately 64.0% to approximately 60.5%. The Supplier Agreement provides, among other things, that upon PF Medical’s commercialization of certain Tc99m generators, Digirad will purchase agreed upon quantities of Tc-99m for its nuclear imaging operations either directly or in conjunction with its preferred nuclear pharmacy supplier and ~~Perma-Fix~~PF Medical will supply Digirad, or its preferred nuclear pharmacy supplier, with Tc-99m at a preferred pricing, subject to certain conditions.

Investing Activities

For the ~~six~~nine months ended ~~June~~September 30, 2015, our purchases of capital equipment totaled approximately ~~$265,000.~~$338,000. These expenditures were primarily for improvements in our Treatment Segment. These capital expenditures were funded by cash from operations and the net borrowing on our revolving credit facility. We have budgeted approximately $1,100,000 for 2015 capital expenditures for our ~~Segments~~segments to maintain operations and regulatory compliance requirements. Certain of these budgeted projects may either be delayed until later years or deferred altogether. We have traditionally incurred actual capital spending totals for a given year at less than the initial budgeted amount. We plan to fund our capital expenditures from cash from operations and/or additional financing. The initiation and timing of projects are also determined by financing alternatives or funds available for such capital projects.

~~Related Party Transactions~~

~~Mr. John Climaco.~~

On June 2, 2015, Mr. Climaco was elected as the Executive Vice President of PF Medical. Mr. Climaco will receive an annual salary from PF Medical of $150,000. Mr. Climaco currently serves as a Director of the Company and a member of the Strategic Advisory Committee of the Board. .

On October 17, 2014, the Company’s Compensation Committee and the Board, with Mr. Climaco abstaining, approved a consulting agreement with John Climaco. Pursuant to the consulting agreement, Mr. Climaco was responsible to, among other things:

●

~~Review the Company’s operations to restructure costs to render the Company more competitive;~~

●

~~Evaluate all functions, including but not limited to sales, marketing, accounting, operations, and executive management as well as cost structures for each facility;~~

●

~~Assist in the development of the Company’s strategy opportunity and other initiatives, including but not limited to the development of the Company’s medical isotope technology; and~~

●

~~Other assignments as determined by the Board.~~

Mr. Climaco was paid $22,000 per month under the consulting agreement, beginning September 2014. This consulting agreement was terminated effective June 2, 2015, upon Mr. Climaco’s election as Executive Vice-President of PF Medical, discussed above.

Mr. Climaco is also a director of Digirad Corporation. On July 24, 2015, PF Medical entered into a multi-year Tc-99m Supplier Agreement and a Subscription Agreement with Digirad Corporation (see “Financing Activities” above for further information regarding these Agreements).

Off Balance Sheet Arrangements

We have a number of routine operating leases, primarily related to office space rental, office equipment rental and equipment rental for contract projects as of ~~June~~September 30, 2015, which total approximately ~~$1,891,000,~~$1,734,000, payable as follows: ~~$352,000~~$195,000 in remainder of 2015; $675,000 in 2016; $670,000 in 2017; with the remaining $194,000 in 2018.

From time to time, we are required to post standby letters of credit and various bonds to support contractual obligations to customers and other obligations, including facility closures. As of ~~June~~September 30, 2015, the total amount of these bonds and letters of credit outstanding was approximately $1,773,000, of which the majority of the amount relates to various bonds. Our Treatment Segment facilities operate under licenses and permits that require financial assurance for closure and post-closure costs. We provide for these requirements through financial assurance policies. As of ~~June~~September 30, 2015, the closure and post-closure requirements for these facilities were approximately ~~$46,388,000.~~$46,404,000. We have recorded approximately ~~$21,351,000~~$21,364,000 in a sinking fund related to these policies in other long term assets on the accompanying Consolidated Balance Sheets.

~~Critical Accounting~~~~Policies and~~~~Estimates~~

~~There were no significant changes in our accounting policies or critical accounting estimates that are discussed in our Annual Report on Form 10-K for the year ended December 31, 2014.~~

Known Trends and Uncertainties

Significant Customers. Our segments have significant relationships with the federal government, and continue to enter into contracts, directly as the prime contractor or indirectly as a subcontractor, with the federal government. The contracts that we are a party to with the federal government or with others as a subcontractor to the federal government generally provide that the government may terminate or renegotiate the contracts on 30 days notice, at the government's election. Our inability to continue under existing contracts that we have with the federal government (directly or indirectly as a subcontractor) could have a material adverse effect on our operations and financial condition.

We performed services relating to waste generated by the federal government, either directly as a prime contractor or indirectly as a subcontractor to the federal government, representing approximately ~~$9,872,000~~$9,460,000 or ~~60.4%~~54.7% and ~~$17,756,000~~$27,261,000 or ~~59.3%~~57.7% of our total revenue from continuing operations during the three and ~~six~~nine months ended ~~June~~September 30, 2015, respectively, as compared to ~~$7,556,000~~$11,734,000 or ~~59.7%~~69.4% and ~~$12,843,000~~$24,576,000 or ~~55.4%~~61.3% of our total revenue from continuing operations during the corresponding period of 2014, respectively.

Environmental Contingencies

We are engaged in the waste management services segment of the pollution control industry. As a participant in the on-site treatment, storage and disposal market and the off-site treatment and services market, we are subject to rigorous federal, state and local regulations. These regulations mandate strict compliance and therefore are a cost and concern to us. Because of their integral role in providing quality environmental services, we make every reasonable attempt to maintain complete compliance with these regulations; however, even with a diligent commitment, we, along with many of our competitors, may be required to pay fines for violations or investigate and potentially remediate our waste management facilities.

We routinely use third party disposal companies, who ultimately destroy or secure landfill residual materials generated at our facilities or at a client's site. In the past, numerous third party disposal sites have improperly managed waste and consequently require remedial action; consequently, any party utilizing these sites may be liable for some or all of the remedial costs. Despite our aggressive compliance and auditing procedures for disposal of wastes, we believe we could further be notified, in the future, that we are a potentially responsible party (“PRP”) at a remedial action site, which could have a material adverse effect.

Our subsidiaries where the remediation expenditures will be made are the ~~Leased Property~~former Environmental Processing Services, Inc. (“EPS”) site in Dayton, Ohio, a former Resource Conservation and Recovery Act (”RCRA”) storage facility as operated by the former owners of Perma-Fix Dayton, Inc. (“PFD”), Perma-Fix of Memphis Inc.’s (“PFM” – closed location) site in Memphis, Tennessee, PFSG facility in Valdosta, Georgia (in closure status), and Perma-Fix Michigan, Inc.’s (“PFMI” – closed location) site in Brownstown, Michigan. The environmental liability of PFD (as it relates to the remediation of the ~~storage facility~~EPS site assumed by the Company as a result of the original acquisition of the PFD facility) was retained by the Company upon the sale of PFD in March 2008. All of the reserves noted above are within our discontinued operations. While no assurances can be made that we will be able to do so, we expect to fund the expenses to remediate these sites from funds generated internally.

At ~~June~~September 30, 2015, we had total accrued environmental remediation liabilities of ~~$996,000,~~$976,000, of which ~~$627,000~~$87,000 is recorded as a current liability, which reflects a decrease of ~~$20,000~~$40,000 from the December 31, 2014 balance of $1,016,000. The decrease represents payments on remediation projects. In connection with the Purchase Agreement dated September 29, 2015 for the sale of the property at PFMI, the Company will remain responsible for site remediation activities pursuant to a consent order unless and until the activities are completed or transferred to the new property owner subject to the approval of the Michigan Department of Environmental Quality (“MDEQ”). At September 30, 2015, the remediation reserve balance at PFMI was approximately $77,000 (all current) which is anticipated to be used during the fourth quarter of 2015 for final closure activities approved by the Michigan Department of Environmental Quality during August 2015. At September 30, 2015, the remediation reserve balance at PFSG (which was officially in closure status effective August 28, 2015) was approximately $816,000, of which approximately $6,000 is recorded as current liability (see “Discontinued Operations and Divestitures” in this “Management‘s Discussion and Analysis of Financial Condition and Results of Operations” for the Purchase Agreement regarding PFMI and PFSG’s closure status).

Item3.

Quantitative and Qualitative Disclosures about Market Risks

Not required for smaller reporting companies.

Item 4.

Controls and Procedures


(a)	Evaluation of disclosure controls and procedures.

	We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management. As of the end of the period covered by this report, we carried out an evaluation with the participation of our Principal Executive Officer and Principal Financial Officer. Based on this recent assessment, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) were not effective, as a result of the identified material weakness in our internal control over financial reporting as set forth below.


	●		The Company identified a material weakness in the operational effectiveness of controls in the accounting for income taxes primarily due to its limited in-house tax expertise and its over-reliance on a third party tax professional firm. This material weakness resulted in a revision to our 2013 opening balance of accumulated deficit in our Consolidated Statements of Stockholders’ Equity and revisions to certain deferred tax assets and liabilities accounts in our Consolidated Balance Sheet as of December 31, 2013. This material weakness, if not remediated, has a potential to cause future material misstatements to be undetected.


	We have implemented the following controls and procedures which we believe will remediate the material weakness above in the ~~third~~fourth quarter of 2015.


1.	~~Management will provide increased~~ Increased review and monitoring by management of the Company’s income tax filings and provisions, which will include utilization of a checklist to help ensure all major income tax components are accounted for during the review process.
		2.	Our tax filing and tax provision function ~~which will be~~are performed by separate third party tax professional firms which will further assist with oversight of our income tax provision preparation procedures.

(b)	Changes in internal control over financial reporting.

	Except as described above, there ~~was~~were no ~~change~~changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) in the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

Item1.

Legal Proceedings

There are no additional material legal proceedings pending against us and/or our subsidiaries not previously reported by us in Item 3 of our Form 10-K for the year ended December 31, 2014 ~~except as follows:~~

~~On May 11,~~and our Form 10-Q for the quarters ended March 31, 2015 the Company’s Perma-Fix of South Georgia, Inc. subsidiary (“PFSG”) received a Consent Order (“CO”) from the Georgia Department of Natural Resources Environmental Protection Division (“GAEPD”), which alleged certain violations of Georgia Rules for Hazardous Waste Management and the PFSG Hazardous Waste Permit. The CO also established the process for formerly closing the PFSG hazardous waste management facilities, should PFSG elect to do so. The CO requests payment of $201,200 as penalty for these alleged violations which was paid by the Company and recorded in the three months ended June 30, ~~2015. Pursuant to the CO, PFSG shall have 60 days from July 1,~~ 2015, to provide notification of final closure of the entire facility or intent to resume hazardous waste management operations; and 90 days from July 1, 2015 to submit a post closure plan in the event PFSG decides to proceed with final closure of the facility.The Company has begun initiating full closure requirements of the facility which ~~will include submittal of a post closure plan to be approved~~are incorporated herein by ~~GAEPD.~~reference.

Item1A.

Risk Factors

There has been no other material change from the risk factors previously disclosed in our Form 10-K for the year ended December 31, 2014.

Item 6.

~~Exhibits~~

(a)	Exhibits
	Exhibits
	31.1	Certification by Dr. Louis F. Centofanti, Chief Executive Officer of the Company pursuant to Rule 13a-14(a) or 15d-14(a).
	31.2	Certification by Ben Naccarato, Chief Financial Officer of the Company pursuant to Rule 13a-14(a) or 15d-14(a).
	32.1	~~Certification by~~Certificationby Dr. Louis F. Centofanti, Chief Executive Officer of the Company furnished pursuant to 18 U.S.C. Section 1350.
	32.2	Certification by Ben Naccarato, Chief Financial Officer of the Company furnished pursuant to 18 U.S.C. Section 1350.
	101.INS	XBRL Instance Document*
	101.SCH	XBRL Taxonomy Extension Schema Document*
	101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document*
	101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*
	101.LAB	XBRL Taxonomy Extension Labels Linkbase Document*
	101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document*

			* Pursuant to Rule 406T of Regulation S-T, the Interactive Data File in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

		PERMA-FIX ENVIRONMENTAL SERVICES


Date: ~~August 6,~~November 4, 2015	By:	/s/ Dr. Louis F. Centofanti
		Dr. Louis F. Centofanti
		President and Chief ~~(Principal)~~ Executive Officer

Chief Executive Officer

Date: ~~August 6,~~November 4, 2015	By:	/s/ Ben Naccarato
		Ben Naccarato
		Chief ~~(Principal)~~ Financial Officer and Chief Accounting Officer

3533

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer,” “accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ☐ Accelerated Filer ☐ Non-accelerated Filer ☐ Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of Common Stock, as of the close of the latest practical date.

PART I~~FINANCIAL INFORMATION~~	FINANCIAL INFORMATION		Page No.

~~Item 1.~~		~~Consolidated Condensed Financial Statements (Unaudited)~~

		~~Consolidated Balance Sheets -June 30, 2015 and December 31, 2014~~	1

		~~Consolidated Statements of Operations -Three and Six Months Ended June 30, 2015 and 2014~~	3

		~~Consolidated Statements of Comprehensive (Loss) Income -Three and Six Months Ended June 30, 2015 and 2014~~	4

		~~Consolidated Statements of Stockholders’ Equity -Six Months Ended June 30, 2015~~	5

		~~Consolidated Statements of Cash Flows -Six Months Ended June 30, 2015 and 2014~~	6

		~~Notes to Consolidated Financial Statements~~	7

~~Item 2.~~		~~Management's Discussion and Analysis ofFinancial Condition and Results of Operations~~	20

~~Item 3.~~		~~Quantitative and Qualitative DisclosuresAbout Market Risk~~	33

~~Item 4.~~		~~Controls and Procedures~~	33

~~PART II~~ ~~OTHER INFORMATION~~	Item 1.	Consolidated Condensed Financial Statements (Unaudited)	1

		Consolidated Balance Sheets - September 30, 2015 and December 31, 2014

~~Item 1.~~		~~Legal Proceedings~~Consolidated Statements of Operations - Three and Nine Months Ended September 30, 2015 and 2014	34 3

~~Item 1A.~~		~~Risk Factors~~Consolidated Statements of Comprehensive Income (Loss) - Three and Nine Months Ended September 30, 2015 and 2014	34 4

~~Item 6.~~		~~Exhibits~~Consolidated Statements of Stockholders’ Equity - Nine Months Ended September 30, 2015	34 5

		Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2015 and 2014	6

		Notes to Consolidated Financial Statements	7

	Item 2.	Management's Discussion and Analysis ofFinancial Condition and Results of Operations	19

	Item 3.	Quantitative and Qualitative DisclosuresAbout Market Risk	31

	Item 4.	Controls and Procedures	32


PART II	OTHER INFORMATION

	Item 1.	Legal Proceedings	32

	Item 1A.	Risk Factors	32

	Item 6.	Exhibits	32

	June 30,			December 31,
(Amounts in Thousands, Except for Share and per Share Amounts)	2015			2014

ASSETS
Current assets:
Cash	$	1,041		$	3,680
Restricted cash		152			85
Accounts receivable, net of allowance for doubtfulaccounts of $1,886 and $2,170, respectively		9,615			8,272
Unbilled receivables - current		5,865			7,177
Inventories		404			498
Prepaid and other assets		2,813			3,010
Deferred tax asset - current		385			385
Current assets related to discontinued operations		22			20
Total current assets		20,297			23,127

Property and equipment:
Buildings and land		20,196			20,362
Equipment		35,631			35,434
Vehicles		403			403
Leasehold improvements		11,613			11,613
Office furniture and equipment		1,828			1,799
Construction-in-progress		380			336
		70,051			69,947
Less accumulated depreciation and amortization		(48,780	)		(47,123	)
Net property and equipment		21,271			22,824

Property and equipment related to discontinued operations		531			681

Intangibles and other long term assets:
Permits		16,751			16,709
Other intangible assets - net		2,214			2,435
Unbilled receivables – non-current		253			273
Finite risk sinking fund		21,351			21,334
Other assets		1,178			1,253
Total assets	$	83,846		$	88,636

	June 30,			December 31,
(Amounts in Thousands, Except for Share and per Share Amounts)	2015			2014

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	5,485		$	5,350
Accrued expenses		4,212			4,540
Disposal/transportation accrual		1,412			1,737
Deferred revenue		3,321			4,873
Current liabilities related to discontinued operations		2,042			2,137
Current portion of long-term debt		2,310			2,319
Current portion of long-term debt - related party		1,414			1,414
Total current liabilities		20,196			22,370

Accrued closure costs		5,237			5,508
Other long-term liabilities		835			803
Deferred tax liabilities		5,462			5,391
Long-term liabilities related to discontinued operations		675			590
Long-term debt, less current portion		7,220			6,690
Long-term debt, less current portion - related party		242			949
Total long-term liabilities		19,671			19,931

Total liabilities		39,867			42,301

Commitments and Contingencies (Note 8)

Series B Preferred Stock of subsidiary, $1.00 par value; 1,467,396 sharesauthorized, 1,284,730 shares issued and outstanding, liquidationvalue $1.00 per share plus accrued and unpaid dividends of $835and $803, respectively		1,285			1,285

Stockholders' Equity:
Preferred Stock, $.001 par value; 2,000,000 shares authorized, no shares issued and outstanding		—			—
Common Stock, $.001 par value; 30,000,000 shares authorized;11,512,783 and 11,476,485 shares issued, respectively;11,505,141 and 11,468,843 shares outstanding, respectively		11			11
Additional paid-in capital		103,958			103,765
Accumulated deficit		(61,976	)		(59,758	)
Accumulated other comprehensive (loss) income		(63	)		11
Less Common Stock in treasury, at cost; 7,642 shares		(88	)		(88	)
Total Perma-Fix Environmental Services, Inc. stockholders' equity		41,842			43,941
Non-controlling interest		852			1,109
Total stockholders' equity		42,694			45,050

Total liabilities and stockholders' equity	$	83,846		$	88,636

	September 30,			December 31,
(Amounts in Thousands, Except for Share and per Share Amounts)	2015			2014

ASSETS
Current assets:
Cash	$	1,998		$	3,680
Restricted cash		102			85
Accounts receivable, net of allowance for doubtfulaccounts of $1,880 and $2,170, respectively		8,462			8,272
Unbilled receivables - current		5,732			7,177
Inventories		350			498
Prepaid and other assets		3,696			3,010
Deferred tax asset - current		385			385
Current assets related to discontinued operations		37			20
Total current assets		20,762			23,127

Property and equipment:
Buildings and land		20,196			20,362
Equipment		35,677			35,434
Vehicles		421			403
Leasehold improvements		11,628			11,613
Office furniture and equipment		1,832			1,799
Construction-in-progress		356			336
		70,110			69,947
Less accumulated depreciation and amortization		(49,575	)		(47,123	)
Net property and equipment		20,535			22,824

Property and equipment related to discontinued operations		531			681

Intangibles and other long term assets:
Permits		16,775			16,709
Other intangible assets - net		2,124			2,435
Unbilled receivables – non-current		364			273
Finite risk sinking fund		21,364			21,334
Other assets		1,141			1,253
Total assets	$	83,596		$	88,636

	Common Stock						Common			Accumulated			Non-
(Amounts in thousands, except for share amounts)	Shares		Amount		Additional Paid-In Capital		Stock Held In Treasury			Other Comprehensive Income (Loss)			controlling Interest in Subsidiary			Accumulated Deficit			Total Stockholders' Equity

Balance at December 31, 2014		11,476,485	$	11	$	103,765	$	(88	)	$	11		$	1,109		$	(59,758	)	$	45,050
Net loss		—		—		—		—			—			(487	)		(1,148	)		(1,635	)
Foreign currency translation		—		—		—		—			(92	)		—			—			(92	)
Perma-Fix Medical S.A.(proceeds from stock subscription, net ofexpenses of $29)		—		—		—		—			—			1,038			—			1,038
Issuance of Common Stock uponexercise of options		3,423		—		10		—			—			—			—			10
Issuance of Common Stock forservices		55,459		—		220		—			—			—			—			220
Stock-Based Compensation		—		—		62		—			—			—			—			62
Balance at September 30, 2015		11,535,367	$	11	$	104,057	$	(88	)	$	(81	)	$	1,660		$	(60,906	)	$	44,653

	Nine Months Ended September 30,
(Amounts in Thousands)	2015			2014
Cash flows from operating activities:
Net loss	$	(1,635	)	$	(2,087	)
Less: (loss) income on discontinued operations		(1,313	)		1,633

Loss from continuing operations		(322	)		(3,720	)
Adjustments to reconcile net loss from continuing operations to cash provided by (used in) operations:
Depreciation and amortization		2,821			3,282
Amortization of debt discount		65			65
Deferred tax expense		107			90
(Recovery of) provision for bad debt reserves		(27	)		11
Impairment loss on goodwill		—			380
Gain on disposal of plant, property and equipment		(23	)		(41	)
Loss on sale of SYA subsidiary		—			48
Issuance of common stock for services		220			198
Stock-based compensation		62			(2	)
Changes in operating assets and liabilities of continuing operations:
Accounts receivable		(164	)		(1,960	)
Unbilled receivables		1,354			(1,246	)
Prepaid expenses, inventories and other assets		795			709
Accounts payable, accrued expenses and unearned revenue		(3,404	)		801
Cash provided by (used in) continuing operations		1,484			(1,385	)
Cash used in discontinued operations		(1,233	)		(1,959	)
Cash provided by (used in) operating activities		251			(3,344	)

Cash flows from investing activities:
Purchases of property and equipment		(338	)		(375	)
Proceeds from sale of property and equipment		27			133
Proceeds from sale of SYA subsidiary (Note 11)		50			1,218
Payment to finite risk sinking fund		(30	)		(19	)
Cash (used in) provided by investing activities of continuing operations		(291	)		957
Proceeds from property insurance claims of discontinued operations		—			5,727
Cash (used in) provided by investing activities		(291	)		6,684

Cash flows from financing activities:
Borrowing of revolving credit		49,783			60,899
Repayments of revolving credit borrowings		(49,476	)		(60,899	)
Principal repayments of long term debt		(1,742	)		(1,852	)
Principal repayments of long term debt - related party		(1,125	)		(125	)
Proceeds from stock subscription - Perma-Fix Medical S.A., net of expenses of $29		971			—
Proceeds from issuance of common stock		10			4
Cash used in financing activities of continuing operations		(1,579	)		(1,973	)
Principal repayments of long term debt for discontinued operations		—			(27	)
Cash used in financing activities		(1,579	)		(2,000	)

Effect of exchange rate changes on cash		(63	)		—

(Decrease) increase in cash		(1,682	)		1,340
Cash at beginning of period		3,680			333
Cash at end of period	$	1,998		$	1,673

Supplemental disclosure:
Interest paid	$	404		$	498
Income taxes paid		116			30
Proceeds from stock subscription for Perm-Fix Medical S.A. held in escrow		67			—

	Common Stock				Additional		Common Stock			Accumulated Other			Non-controlling						Total
(Amounts in thousands, except for share amounts)	Shares		Amount		Paid-In Capital		Held In Treasury			Comprehensive Income (Loss)			Interest in Subsidiary			Accumulated Deficit			Stockholders' Equity

Balance at December 31, 2014		11,476,485	$	11	$	103,765	$	(88	)	$	11		$	1,109		$	(59,758	)	$	45,050
Net loss		—		—		—		—			—			(324	)		(2,218	)		(2,542	)
Foreign currency translation		—		—		—		—			(74	)		—			—			(74	)
Perma-Fix Medical S.A.(proceeds from stock subscription receivables)		—		—		—		—			—			67			—			67
Issuance of Common Stock uponexercise of options		2,388		—		7		—			—			—			—			7
Issuance of Common Stock forservices		33,910		—		140		—			—			—			—			140
Stock-Based Compensation		—		—		46		—			—			—			—			46
Balance at June 30, 2015		11,512,783	$	11	$	103,958	$	(88	)	$	(63	)	$	852		$	(61,976	)	$	42,694

			June 30, 2015							December 31, 2014
	Useful		Gross					Net		Gross					Net
	Lives		Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying						September 30, 2015							December 31, 2014
	(Years)		Amount		Amortization			Amount		Amount		Amortization			Amount		Useful Lives (Years)				Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Intangibles (amount in thousands)
Patent		8-18	$	512	$	(186	)	$	326	$	512	$	(168	)	$	344		8	-	18	$	516	$	(194	)	$	322	$	512	$	(168	)	$	344
Software		3		379		(358	)		21		375		(319	)		56			3			379		(360	)		19		375		(319	)		56
Customer relationships		12		3,370		(1,503	)		1,867		3,370		(1,335	)		2,035			12			3,370		(1,587	)		1,783		3,370		(1,335	)		2,035
Permit		10		545		(345	)		200		545		(318	)		227			10			545		(359	)		186		545		(318	)		227
Total			$	4,806	$	(2,392	)	$	2,414	$	4,802	$	(2,140	)	$	2,662					$	4,810	$	(2,500	)	$	2,310	$	4,802	$	(2,140	)	$	2,662

	Amount		Amount
Year	(In thousands)		(In thousands)

2015(remaining)	$	239	$	122
2016		425		425
2017		391		391
2018		361		361
2019		280		280
	$	1,696	$	1,579

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Options outstanding Janury 1, 2015		239,023		$	7.81
Granted		—			—
Exercised		(2,388	)		2.79			$	3,248
Forfeited/expired		(15,000	)		7.10
Options outstanding end of period⁽¹⁾		221,635			7.91		4.7	$	18,869
Options exercisable at June 30, 2015⁽¹⁾		166,635		$	8.88		4.6	$	18,869
Options vested and expected to be vested at June 30, 2015		212,835		$	8.04		4.7	$	18,869

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Options outstanding Janury 1, 2014		362,800		$	9.53
Granted		—			—
Exercised		—			—				—
Forfeited/expired		(62,000	)		7.96
Options outstanding end of period⁽¹⁾		300,800			9.85		2.8	$	41,070
Options exercisable at June 30, 2014⁽¹⁾		300,800		$	9.85		2.8	$	41,070
Options vested and expected to be vested at June 30, 2014		300,800		$	9.85		2.8	$	41,070